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Abstract 
Prostate cancer patients' reactions to out-of-pocket travel and drug costs in 
Newfoundland and Labrador 
Introduction - How much do prostate cancer patients pay out of pocket for cancer care 
and how do they manage these costs? To examine: 
1) out-of-pocket costs for drugs and travel 
2) the use of cost management strategies 
3) differences in out-of-pocket drug costs and use of cost reduction strategies between 
urban and rural patients, 
Methods- Using a self-administered questionnaire, we surveyed 170 men with prostate 
cancer in NL. 
Conclusion - A small but substantial proportion of men with prostate cancer had 
substantial costs. Almost 1 in 5 men (18.8%) paid more than $500 in the last quarter. For 
roughly 1 in 6, these OOP costs accounted for more than 7.5% oftheir quarterly income. 
Aside from higher stress related to OOP costs, there were few other differences in the use 
of cost saving strategies, quality oflife or attitudes of urban and rural men. 
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Chapter 1 
1.1. Problem and Research Question 
As rates of cancer are increasing in the province of Newfoundland and 
Labrador and across Canada (Canadian Cancer Society [CCS], 2004a), there is a 
growing need to understand the financial burden associated with the disease and its 
impact on patients. Out of pocket (OOP) expenses are costs associated with cancer 
treatment that are not covered by insurance (Cohn, Goodenough, Foreman, & 
Suneson, 2003; Moore, 1998) and can include financial implications from expenses 
from travel and accommodation to loss of income, medications, and home care. 
(Mathews, West, & Buehler, 2009a; Cohn et al., 2003). 
This study focuses on men in Newfoundland and Labrador who have been 
diagnosed with prostate cancer, one of the major cancers for men (CCS, 2009a). A 
primary treatment of prostate cancer is radiation therapy (Carroll, Carducci, Zietman, 
& Rothaermel, 2005), and in Newfoundland and Labrador, the only radiation therapy 
clinic is in St. John's (Mathews et al, 2009a). Rural residents are required to travel to 
and stay in St. John's in order to access these treatments, often at their own expense. 
In addition, prostate cancer patients may receive hormone therapy for extended 
periods of time, almost always on an out-patient basis. Patients therefore, bear the 
auxilliary costs of these often expensive drug regimens. This study will describe the 
types and amounts of OOP costs incurred by prostate cancer patients. It will also 
examine whether OOP costs of prostate cancer have any effect on patients' cost 
management strategies, attitudes and quality of life. 
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1.2. Objectives 
The purpose of this study was to examine the OOP costs associated with 
prostate cancer patients in Newfoundland and Labrador and to describe any 
differences that might exist between patients living in urban and rural areas. 
Specifically the objectives of this study were: 
1. to identify the types and magnitude of OOP costs incurred by prostate cancer 
patients 
2. to describe patients' strategies to manage OOP costs for prostate cancer care 
3. to determine whether OOP costs affect patients' attitudes, and quality oflife 
4. to examine differences between urban and rural prostate cancer patients in the 
types and amounts of OOP costs, management strategies, attitudes, and quality 
of life. 
1.3. Rationale 
In the next 30 years, cancer will be a leading health concern in Canada with as 
many as two in five Canadians facing a diagnosis during their lives (CCS, 2004a). 
Prostate cancer rates continue to rise in Newfoundland and Labrador. In 2004, it was 
estimated that there would be 310 new cases of prostate cancer in the province ( CCS, 
2004b) and in 2009 incidence is projected to increase to 480 new cases (CCS, 2009b), 
representing an 54.8% increase in the number of cases over five years. 
As cancer rates increase, so does the need to understand OOP costs associated 
with cancer and their impact on patients. There is limited information on the OOP 
expenses incurred while undergoing cancer treatment (Langa et al., 2004) as well as 
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the effects these hidden costs have on patients' treatment compliance and outcomes 
(Moore, 1999). A literature review of existing research on OOP costs of cancer, 
found that these studies have been primarily concerned with costs to the health care 
system rather than costs to the patient (Lauzier et al, 2005). 
Previous studies have found that OOP costs can affect the decisions cancer 
patients make regarding their treatment. Guidry, Aday, Zhang, and Winn (1997, 
1998) found that patients may alter or take more drastic measures such as foregoing 
treatments due to the OOP costs of cancer. The economic burden placed on those 
suffering from cancer can add to the concerns about the disease as well as survival 
(Lauzier et al., 2005). 
OOP costs of cancer also differ depending on the type of cancer and 
subsequent treatment. Lauzier and colleagues (2005) noted that those receiving 
radiotherapy, as is the case for most prostate cancer patients (Carroll, Carducci, 
Zietman, & Rothaermel, 2005), can have increased costs related to expenses such as 
travel and longer stays while receiving treatment. The elderly, rural residents, and the 
working poor may be at a greater risk of having high OOP costs than their younger, 
urban, or wealthier counterparts. Cancer is known primarily as a disease of the aging 
with 88% of new cancer cases in 2009 occurring in Canadians over the age of 50 
(CCS, 2009b ). 
Canadian studies have found that cancer patients living in rural areas are more 
vulnerable to OOP costs as costs increase for those living more than one hour away 
from the hospital where treatment is received (Cohn et al., 2003; Lauzier et al., 2005; 
Mathews et al, 2009a). Moreover, rural residents are more likely to have more 
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children and lower average incomes (Fellegi, 1996) than urban residents. Compared 
to those in higher socio-economic groups, those in lower socio-economic groups, 
such as the working poor, will be more affected by the burden of OOP costs, as a 
greater percentage of their income will be consumed by these costs (Bernard, 
Banthin, & Encinosa 2006; Moore, 1998; Wagner & Lacey, 2004). In addition, the 
working poor and rural residents are less likely to have employment related private 
health insurance that may offset some OOP expenses, particularly for drugs. Moore 
(1998) has noted a relationship between poverty, cancer and loss oflife. Similarly, 
Wagner and Lacey (2004) found that patients of a lower socio-economic status had a 
lower survival rate. 
Since cancer rates increase with age, assessing the impact of OOP for cancer 
care is particularly relevant in Newfoundland and Labrador, with its ageing 
population. In 2000, 11.6% ofthe total population ofNewfoundland and Labrador 
were seniors, (i.e. those over the age of 65). It is projected that in 2021 this figure is 
projected to grow to 22.5% (Economics and Statistics Branch, 2005). In 2005, the 
average age for a resident of Newfoundland and Labrador was 40.5 years; it is 
projected that the average age will increase to 49.2 by 2031 (Statistics Canada, 
2005a). 
Newfoundland and Labrador has several other demographic factors that are 
relevant when assessing the impact of OOP costs of cancer. Over 40% of its residents 
live in rural communities (Statistics Canada, 2008). In 2004 the median after tax 
income for families of two or more in NL falls well below the Canadian average 
$61,800 (Statistics Canada, 2007a). In fact, in 2007, the province had a median after-
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tax income of $50,900, the second lowest in the country next to New Brunswick with 
a median after-tax income of$50,600 (Statistics Canada, 2007a). This study increases 
our understanding of how cancer patients and their families manage the financial 
burden associated with cancer care. It provides health care providers, system 
administrators and patient advocates with evidence with which to improve the 
accessibility of cancer care in the province. 
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Chapter 2: Review of the Literature 
2.1. Prostate cancer 
In 2009, 32% of men in NL are estimated to be diagnosed with cancer, and of 
those estimated to be diagnosed with cancer in 2009, 17.8% will receive a diagnosis 
of prostate cancer, the most commonly diagnosed cancer for men (CCS, 2009b ). 
Prostate cancer begins in the glandular tissue of the prostate, part of the male sexual 
reproductive system, and is called adenocarcinoma. The prostate is about the size of 
walnut and is found at the base of the penis underneath the bladder (CCS, 2006a). 
The main function of the prostate is to produce seminal fluid (CCS, 2006a). 
Prostate cancer tumours grow slowly and can take from five to 15 years to 
spread (metastasize) from the prostate to other organs in the body. The symptoms of 
prostate cancer vary depending on the stage of the disease which indicates whether or 
not the cancer has spread beyond the prostate. Signs of prostate cancer include 
changes to urination, blood in urine or semen and/or pain during ejaculation (CCS, 
2006b). Symptoms of metastatic prostate cancer include bone pain, weight loss and 
fatigue (CCS, 2006b). 
The process of diagnosis generally begins once a man has presented to his 
physician with specific complaints, or irregularities are detected during regular 
examinations. Routine screening is done with a digital rectal exam (DRE) and/or a 
prostate specific antigen (PSA) test. The DRE is recommended annually, by the 
American Cancer Society and American Urology Association, for all men over 50 
years of age. Men with an elevated risk of prostate cancer (e.g. family history) should 
also have annual DRE (Prostate Disorders, 2006; Jamnicky & Nam, 2003). The PSA 
6 
test is a blood test used to aid in diagnosing cancer (CCS, 2006b ). Prostate cancer 
cells produce a greater number of PSA than normal cells; levels below 4ng/mL are 
considered normal. Elevated PSA levels may indicate prostate cancer1 (Jamnicky & 
Nam, 2003). Currently, the PSA test is not recommended by most guidelines, 
particularly for men over the age of 70 who are expected to have less than a ten year 
life expectancy, in which case the immediate harms of detection and treatment 
outweigh the potential benefits (Walter, Bertenthal, Lindquist, & Kovety, 2006). 
There does not appear to be conclusive evidence to indicate that the PSA test lowers 
mortality or life-expectancy from prostate cancer. Moreover, the test has high levels 
of false negative and false positive results (Walter et al, 2006; Ilic, O'Connor, Green, 
& Witt, 2006). If DRE and PSA suggest prostate cancer may be present, transrectal 
ultrasound (TRUS) may be used to determine the size of the prostate and see any 
obvious tumours (CCS, 2006a; Jamnicky & Nam, 2003). 
The only definite way of determining whether or not prostate cancer is present 
is through a needle biopsy (Jamnicky & Nam, 2003). Ultrasound is used to aid the 
physician in guiding the biopsy needle to the prostate gland in order to obtain small 
pieces of tissue from the prostate. Once tissue samples have been obtained, a 
pathologist examines the samples and determines whether or not cancer is present 
(Jamnicky & Nam, 2003). 
Once the cancer has been diagnosed the stage and aggressiveness are 
determined. Stage refers to the size of the tumour and whether or not cancer has 
spread to other parts of the body. The TNM staging system has four stages with 
1 This is a reference point and men with lower levels may have prostate cancer (Jamnicky & Nam, 
2003) 
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various levels within. The stage is determined by assessing T (tumour size), N 
(involvement oflymph nodes), and M (metastases) (Jamnicky & Nam, 2003). 
Staging is represented by a series of numbers from zero to four, higher numbers 
indicating a cancer that has spread (CCS, 2006c). The TNM and number system of 
staging can be combined in order to indicate severity for each aspect (i.e. Tl NOMO). 
Determining the stage of cancer is important, as it will help in deciding which 
treatment option is best for the patient. Other tests will be done if it is suspected that 
the cancer has spread. Tests to find any tumours outside of the prostate include 
computerized axial tomography (CT) scans, magnetic resonance imaging (MRI) and 
bone scans (Jamnicky & Nam, 2003). 
The Gleason score is also used in prostate cancer to assess the aggressiveness 
of the tumor, (i.e. how likely the cancer is to metastasize). The Gleason score is a 
number between one and ten, ten being the highest and indicating a very aggressive 
cancer, while a score between 2 and 5 is an indication that the tumour is most likely 
benign (Jamnicky & Nam, 2003). 
Once a diagnosis has been given and the stage of the disease has been 
determined, prognosis can be assessed (CCS, 2006b ). Factors that influence 
prognosis include the size of the tumour, the stage and the grade- which is an 
indication of whether or not the cancerous cells resemble normal cells or whether or 
not they have been behaving aggressively (CCS, 2006b ). Once someone has been 
diagnosed and the prognosis has been determined, the next step is to determine 
treatment options. For example, the younger the individual, the more likely he is to 
8 
be a candidate for surgery or radiation as the cancer has had less time to spread 
(Jamnicky & Nam, 2003). 
There are five main options for treating prostate cancer; the wait-and-see 
approach (otherwise known as watchful waiting), radiation therapy, hormonal 
therapy, surgery, and chemotherapy (Jamnicky and Nam, 2003). Treatment can 
consist of several of the available methods and depends on stage of disease as well as 
age, general health and the preference of the patient (CCS, 2006b). Watchful 
waiting2 is a matter of waiting for signs and symptoms to occur at which point 
treatment may be administered. This option may be more readily used for elderly 
men who have non-aggressive tumours or in the case where the adverse effects of 
other forms of treatment are worse than the symptoms (CCS, 2006b). 
Several types of radiation therapy are used to treat prostate cancer including 
external beam radiotherapy. This form of therapy directs radiation at the prostate 
from outside the body. External beam radiotherapy requires short treatments often to 
15 minutes, five days a week, for up to seven or eight weeks (Jamnicky & Nam, 
2003). External beam radiotherapy is used as a curative therapy for those with an 
early stage cancer. It is also used as an adjuvant therapy following surgery with the 
goal of destroying any cancer cells that have not removed by surgery, lowering the 
risk of recurrence, and relieving pain and symptoms of more advanced prostate 
cancer (CCS, 2006b ). Other forms of radiation, such as brachytherapy and 
radioactive isotopes, administer radiation from within the body removing the need to 
return for treatment day after day. Radiation is directed at the cancerous tissue which 
2 
"Watchful waiting is also called active surveillance. In this thesis, we use the term active treatment 
to refer to chemotherapy, radiation therapy, surgery, or hormone therapy." 
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does not repair as quickly as healthy tissue, destroying the cancerous cells while 
allowing for the areas around the treated region to recover (Jamnicky & Nam, 2003). 
Hormone therapy may be used to treat prostate cancer as prostate cancer 
grows in response to male hormones, called androgens. Controlling hormone levels 
in the body can slow the growth and spread of cancerous cells. Hormones that are 
controlled in prostate cancer therapy include luteinizing hormone-releasing hormone 
(LHRH) agonists, and antiandrogens. Hormone control can be achieved through 
either drugs (to suppress production of male hormones) or surgery, specifically 
orchiectomy which is the removal of the testicles. Hormone therapy is often used 
before and after radiation therapy and for those who have high risk cases of prostate 
cancer (CCS, 2006b ). 
There are two main forms of prostate surgery used to treat prostate cancer. 
Radical prostatectomy is the complete removal of the prostate gland as well as the 
tissue surrounding the prostate. This form of treatment is often used for men whose 
cancer has not spread, who are under 70 years old, are expected to live for at least 
another ten years and who are healthy enough to undergo the procedure including 
anesthesia (CCS, 2006b ). The goal of a radical prostatectomy is to cure the cancer by 
removing the prostate gland or to relieve the symptoms of the cancer by removing 
some of the tissue (CCS, 2006b ). 
For those who may not be able to undergo a radical prostatectomy due to age 
or health, or for those whose cancer has spread beyond the prostate, Transurethral 
Resection of the Prostate (TURP) is another option (CCS, 2006b ). The TURP 
procedure is used to reduce the prostate in size and removes the tissue surrounding 
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the urethra. A thin tube with a light (resectoscope) is inserted into the prostate 
through the urethra and allows the surgeon to see the urethra, prostate and bladder. 
The surgeon will remove excess tissue from the prostate and possibly from around the 
urethra as well (CCS, 2006b). This treatment does not cure cancer but relieves some 
of the symptoms (such as blockage of the urethra) and maybe used in conjunction 
with other treatments such as hormonal therapy. (CCS, 2006b). 
Another option for the treatment of prostate cancer is chemotherapy, or the 
use of"anti-cancer" drugs. These drugs are circulated through the body through an 
intravenous needle in order to kill cancerous cells. Chemotherapy may reach 
cancerous cells which have moved away from the tumour (CCS, 2006b ). 
Chemotherapy is generally given in a clinical trial setting as the drugs used are still 
being studied. This treatment might be useful in the case of prostate cancer patients 
who have become resistant to hormonal therapy, or to relieve pain or symptoms of 
palliative patients (CCS, 2006b ). The drugs most commonly used for chemotherapy 
in various combinations include; docetaxel, paclitaxel, vinblastine, etopside, 
prednisone, and mitoxantrone (CCS, 2006b). 
2.2.Canada Health Care System 
2.2.1.Medicare 
The Canada Health Act (CHA), unanimously passed in 1984, is legislation 
requiring provinces and territories to provide health care services deemed to be 
medically necessary. The services covered by the CHA include hospital and 
physician services as well as drugs used in-hospital (Health Canada, 2002). The 
overarching goal of the CHA is to ensure that all Canadians have "reasonable" access 
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to health care services that are medically necessary without having to pay for the 
services directly. 
The CHA supports five principles; public administration, comprehensiveness, 
universality, portability and accessibility. The Newfoundland and Labrador Medical 
Care Plan (MCP) and the Hospital Insurance Plan cover insured hospital services for 
in-patient and out-patient services. These plans do not cover the cost of drugs and 
supplies prescribed for use outside of a hospital setting. 
A cancer patient receiving radiation therapy or chemotherapy treatment may 
get daily treatments for weeks on end, but as they are treated on an out-patient basis, 
any drugs prescribed that are not administered in-hospital are not covered. These 
may include "supportive drugs" to combat side effects of treatment such as nausea, 
anemia, etc. 
2.2.2. Supplementary provincial health subsidies 
2.2.2.l.Drug Plans 
Provincial and federal drug plans exist in order to support those who may be 
at a disadvantage and would have more difficulty in paying for the costs of drugs 
prescribed for use outside of a hospital setting. Federal plans such as the Non-Insured 
Health Benefits program, Veterans Affairs Canada, and Correctional Services Canada 
cover the cost of drugs for registered Indian and Inuit, veterans, and those 
incarcerated, respectively. Provinces may also provide programs to cover the cost of 
outpatient drugs for its residents. In Newfoundland and Labrador, the Newfoundland 
Prescription Drug Plan (NLPDP) changed in February 2007 to include four programs: 
the Foundation Plan, the 65 Plus Plan, The Access Plan and the Assurance Plan which 
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offer assistance to eligible residents of the province for medications, and in some 
instances medical transportation (Government ofNewfoundland and Labrador, n.d.). 
The Foundation Plan is available for those who qualify for full benefit 
coverage according to the Department of Health and Community Services due to the 
high costs of their prescription drugs. Applicants are eligible if they are over 18 years 
old, residents of the province and receive income support. This program covers the 
ingredient cost with up to a 10% markup on prescriptions costing more than $30 and 
a dispensing fee of no more than $6.503 (Government ofNewfoundland and 
Labrador, n.d.) and also provides basic and non-basic financial supports including 
housing, food and clothing expenses, and childcare. 
The 65 Plus Plan provides coverage for those who qualify with the following; 
being 65 years old and over, receiving the Guaranteed Income Supplement and Old 
Age Security benefits. This plan covers eligible drugs under the NLPDP, which are 
most drugs that require a prescription as well as some over-the-counter drugs 
prescribed by a medical professional. Depending on the listing in the provincial 
governments' drug formulary some drugs are only eligible through special 
authorization - assessed by the Department of Health and Community Services upon 
receiving a request from the prescriber. This plan does not cover dispensing fees 
(Government ofNewfoundland and Labrador, n.d.). 
The Access Plan provides access for eligible prescription medications to 
individuals and families deemed to have low income. There are several income 
thresholds within this program: families with children and a net annual household 
3The income support program, formerly known as social assistance provides health with basic and non-
basic financial supports including housing, food and clothing expenses and childcare. 
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income of $30,000 or less, couples without children and a net annual household 
income of $21,000 or less, and individuals with a net annual household income of 
$19,000 or less. 
And finally, the Assurance Plan was created to aid those financially burdened 
by the high costs of eligible prescription drugs. Based on income level, there is an 
"assurance" to families that OOP drug costs will be capped annually at a certain 
percentage depending on the designated income level. Families with a net income 
less than $39,999 will have a cap of 5% of their net income for eligible drug costs, 
those with a net income between $40,000 and $74,999 will have a cap of7.5% and 
finally those with a net income between $75,000 and $149,999 will have a cap of 
10%. (Government ofNewfoundland and Labrador, n.d.). 
Despite these provincial drug plans, there are some drug and other costs 
associated with cancer care that are not covered and must be paid out of pocket by the 
individual. If an individual is eligible for one of these programs but also has private 
insurance they are required to apply to the private insurance first. 
2.2.2.2.Newfoundland and Labrador's medical travel policy 
In addition to drug plans, most provinces also have some form of medical 
travel subsidy to defray the costs of travel for medically necessary care. These 
policies vary substantially by province with some provinces lacking a program 
altogether. Provinces and territories such as Ontario, Manitoba, Quebec, 
Saskatchewan, Nunavut, the Northwest Territories, the Yukon, and Newfoundland 
and Labrador offer programs to support the costs of travel for medically required 
services. All of the provincial medical travel subsidies require that services have 
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been referred by a physician and are not available in the community of residence. 
The programs vary on which travel costs and how much of those costs they will 
cover. Ontario and Manitoba's medical travel subsidy programs do not cover any 
costs for meals or accommodations, while Newfoundland and Labrador and the 
Yukon offer either per diems and co-payments for costs incurred at a registered 
accommodation, or a maximum daily amount, respectively (Government of 
Newfoundland and Labrador, 2007; Yukon Health and Social Services, 2009). 
In Newfoundland and Labrador, the Medical Transportation Assistance 
Program provides a financial subsidy to provincial residents who are required to 
travel for medically necessary treatment. The program covers 50% of costs for travel, 
and meals after an annual deductible of $400, and 65% once costs exceed $5,000 for 
a one year period.4 However, mileage for private vehicles is not reimbursed. To 
qualify, the treatment must not be available in their health region and must not require 
a minimum stay. Up until January of2006 a minimum stay of 14 days was required. 
Usually, residents are required to travel more than 200km each way to qualify for the 
program; however, shorter distances may be considered in exceptional circumstances 
and where required by a physician to stay overnight. Assistance is available for 
meals and accommodations for those staying in "registered accommodations". Also, 
the Department of Human Resources and Employment pays for all medical travel 
expenses for residents of Newfoundland and Labrador who receive income support or 
temporary support during their cancer treatment (Mathews & Basky, 2004). 
4 Residents of Labrador are exempted from the annual $400 deductible. 
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2.2.3.Private insurance 
In addition to public insurance and subsidy programs, supplemental costs for 
health care are also cost-shared through private health insurance programs such as 
Medavie, (formerly known as Blue Cross). Private insurance is offered as an 
employment benefit, although individuals can purchase insurance on their own, 
although usually at much higher premiums. The costs covered through private 
insurance schemes vary depending on the plan, and range from 100% coverage for 
travel due to medical reasons, as well as 20-30% co-payments on prescription drugs 
with or without an initial $500 deductible depending on the program (Canadian Life 
and Health Insurance Association [CLHIA ], 2006). 
As of 2002, compared to other Canadian provinces, Newfoundland and 
Labrador had the highest percentage of residents, (28%), with no coverage for OOP 
drug expenses at the $5,000 and $20,000 levels of prescription drug expenses (Fraser 
Group/Tristat Resources, 2002). All of the Atlantic provinces had comparable 
percentages of their populations without coverage (for prescription drugs at these 
levels), while no other provinces had residents without coverage. With the addition 
of the Assurance Plan to the provincial government's NLPDP, no resident of 
Newfoundland and Labrador will have more than five to ten per cent of their income 
consumed by OOP costs with incomes ranging from less than $39,999 up to 
$149,999. 
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2.3.0ut of pocket costs for cancer care in general 
2.3.1.Nature of Out ofPocket Costs 
Broadly speaking, OOP costs are costs that are "not covered by government-
based allowance or private insurance" (Cohn et al., 2003). Varricchio (1994) found 
that these costs are not generally included in calculations of medical costs or 
insurance reimbursement while Moore (1998) stated these OOP costs are those 
expenses that remain after insurance requirements have been paid. 
OOP costs can be direct or indirect care related expenses. Direct OOP costs 
include drugs, medical supplies, home care and nutritional supplements (Mathews et 
al., 2009a). Indirect costs include: loss of wages for the patient and family or friends; 
prostheses; wigs; travel costs such as transportation, accommodation, meals, phone 
bills; and care for children and dependent family members (Mathews et al., 2009a; 
Longo, Fitch, Deber, & Williams 2006; Lauzier et al., 2005; Cohn et al., 2003; 
Guidry, Aday, Zhang & Winn, 1998; Moore, 1998; Moore, 1999). 
OOP costs for cancer vary by the type of cancer and the associated treatment 
required (Moore, 1998; Lauzier et al., 2005). Radiation therapy can greatly affect the 
amount of OOP costs related to travel since radiation therapy can entail lengthy stays 
away from home. Radiation therapy can be administered daily for a number of weeks 
and can create significant costs stemming from accommodations and meals for 
patients as well as any family member or friend escorting the patient (Lauzier et al., 
2005). For example, a study of cancer patients in Newfoundland and Labrador found 
that the average length of a stay away from home for radiation therapy was 23.11 
days (Mathews & Basky, 2004). In a study conducted in Ontario on the financial 
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burden of cancer based on the four major types of cancer (breast, colorectal, lung and 
prostate), the average length of time over which treatment was received for prostate 
cancer patients was 339.5 days (Longo et al., 2006) 
2.3.2. Out of pocket costs for prostate cancer 
A survey of breast, prostate, lung and colorectal cancer patients presenting to 
cancer clinics in Newfoundland and Labrador found that OOP costs ranged from $0 
to $5000 per visit; 43.6% of patients receiving radiation therapy reported the costs of 
travel and accommodation to be more than $1000 per visit (Mathews et al., 2009a). 
"Visit" refers to a single trip from the patient's home to the community of the cancer 
clinic rather than an encounter at the cancer clinic. A single visit may include 
multiple encounters with cancer care providers. 
In addition to the costs related to travel, prostate cancer patients may also bear 
the costs of drug treatment that is not administered in-hospital. Drugs prescribed for 
cancer patients to take outside of a hospital situation such as pain medications are not 
covered. Unless the patient is covered by private insurance or one of the available 
assistance programs, such as the Newfoundland and Labrador Prescription Drug 
Program, the patient must pay for these drugs out-of-pocket. For example, costs of 
common medications used to control cancer pain, such as codeine and morphine, 
must be borne by the patient unless they are eligible for the NLPDP or other available 
program (CCS, 2006d) 
2.3.3. Cost Management Strategies 
Previous studies have described the strategies that patients with cancer or 
chronic diseases use to manage OOP costs of care. For example, in a study of older 
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homebound people, Sharkey, Ory, & Browne (2005) reported that 15.8% took less 
medication than prescribed in order to stretch out a prescription, 14% went without 
prescribed medication, 10.8% reported both these strategies (rationing or omitting 
prescribed medications), 30.6% asked their physician for free samples, 23% partially 
filled prescriptions (rather than purchase the full prescription), and 17.6% bought 
only what they thought was the most important of their medications. The study also 
found that almost a third of participants chose between food and medication and that 
a quarter of participants borrowed money or had a family member or friend pay for 
their medications. 
While a US study by Guidry and colleagues (1998) suggested that some 
patients will forego treatment because ofhigh OOP costs, studies from countries with 
public health insurance suggest that patients may opt for radical treatment options in 
an effort to reduce costs. For example, women with breast cancer may choose 
mastectomy over breast conserving surgery to avoid travel costs associated with 
radiation treatment. Several Canadian studies have reported lower rates of breast 
conserving surgery among eligible women who live in rural regions, have longer 
travel times to a cancer treatment centre, or have a low income (Dicks, 1999; Goel et 
al., 1997; Hislop et al., 1996; Iscoe, Goel, Wu, Fehringer, Holowaty, & Naylor ,1994; 
Mackillop et al., 1997). Breast conservation surgery usually requires adjuvant 
radiation therapy that is normally located in larger urban centers. In these studies, 
researchers suggested that the considerable financial and social costs associated with 
this treatment discourage rural patients from choosing breast conservation. Similar 
findings (and rationales) have been reported in studies in Australia (Collins, 1997). A 
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US study reported that those with Medicaid or without insurance were less likely than 
patients with Medicare or private insurance to have breast conserving surgery (Voti, 
Richardson, Reis, Fleming, Mackinnon, & Coeberg, 2006) 
Likewise, the high cost of hormonal therapy for prostate cancer has been 
found to influence both provider and patient treatment decisions. Using a 
convenience sample of U.S. urologists and medical oncologists, Matchar, McCrory, 
and Bennet (1997) found that high OOP costs deterred physicians from prescribing 
hormone treatment such as an androgen agonist (flutamide). At the time of the 1997 
study, meta-analyses reporting no survival benefits for flutamide had not been 
published and physicians had been asked to consider hypothetical cases, assuming 
that flutamide was as effective as other drugs used in hormone therapy. In a 
qualitative study in Newfoundland and Labrador, health providers suggested that men 
may choose orchiectomy (removal of testes) ifthey could not afford the costs of 
ongoing hormone treatment (Mathews, Buehler, & West, 2009b ). These findings 
support an American study of 42 prostate cancer patients who were taking hormonal 
therapy. All participants reported that avoiding orchiectomy was important to them. 
However, if their insurance company did not cover the cost oftreatment, 48% 
indicated that they would discontinue hormonal therapy because they would not be 
able to afford the expense (Chon, Jacobs, & Naslund, 2000). 
In addition to the strategies described above, qualitative interviews of cancer 
care providers in Newfoundland and Labrador found that patients may choose in-
patient palliative care, and work during treatment to minimize loss of income to 
reduce or manage their OOP costs (Mathews, et al., 2009a). Those living in rural 
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areas may take more time between follow-up visits or miss them altogether. In 
response to patients concerns about costs, cancer care providers may change 
treatment protocols or admit patients to hospital. 
A number of studies have described the emotional and social impact of OOP costs 
for cancer care on patients (Guidry et al., 1998; Lauzier et al., 2005; Mathews et al, 
2009b; Moore, 1999). For example, an Australian study of parents of children with 
cancer studied the effects of these costs on lifestyle (Cohn et al., 2003). In response 
to OOP costs, parents gave up a hobby or social activity, reduced their spending for 
special occasions, sold a car, used their work leave or took on a second job. They 
also cut back, or cut out activities such as going out to eat, going to movies, or family 
vacations. Lauzier et al. (2005) described how difficult, if not impossible, it was for 
patients and their families to recover from paying for OOP costs when patients had 
used savings or lost wages from disrupting employment (by either reducing hours 
worked or stopping work completely during and after cancer treatment). 
Few studies have evaluated the outcomes of patients' costs management strategies 
particularly among patients with cancer. In a qualitative study ofhealthcare providers 
and their responses to patients OOP cancer costs, patients may opt for older, less 
expensive but less effective drugs (Mathews et al., 2009b ). A second study by 
Mathews et al (2009a) found that rural cancer patients in Newfoundland and Labrador 
are more likely than urban patients to consider drug, travel and child care costs when 
making decisions regarding their treatment. A US study of diabetics found that 
compliance to the recommended treatment decreases as a result of the burden ofhigh 
OOP costs (Bernard et al., 2006). Moreover, non-compliance led to higher rates of 
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hospitalization and higher costs in the long term (Bernard et al.,2006). Similarly 
Sharkey and colleagues (2005) found that patients who used self-management 
strategies to reduce OOP prescription drug costs used more medical care as a result of 
adverse drug events and unfavorable outcomes (Sharkey et al., 2005). 
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Chapter 3: Methods 
This study used a self-administered questionnaire to survey men with prostate 
cancer in Newfoundland and Labrador. 
3.1. Survey Instrument 
The survey gathered information on each respondent's diagnosis (year, stage, 
and previous cancer diagnoses), treatment (current and previous treatment), OOP 
costs, cost coping strategies, attitudes and beliefs (about costs and drug coverage), 
demographics, and quality of life (using the Functional Assessment of Cancer 
Therapy- Prostate cancer specific scale (FACT -P) (Appendix A). Survey questions 
were based on a review of the literature, questions used in previous studies of cancer 
patients in Newfoundland and Labrador, and in consultation with prostate cancer care 
providers, the Canadian Cancer Society Newfoundland and Labrador Division, 
survivors and prostate cancer support group organizers in the province. 
The FACT -P includes quality oflife items specific to prostate cancer and its 
treatment effects. In addition to a total score, it includes sub-scales for physical well-
being, functional well-being, social well-being, emotional well-being, and satisfaction 
with their relationship with their physician using five point Likert scales plus an 
additional twelve items assessing sexuality, bowel/bladder function, and pain (Cella 
et al. 1993; Esper et al., 1997). Higher scores reflect better quality oflife. The 
instrument is able to distinguish patients at different stages of disease, can be self-
administered or administered by a research assistant in-person or over the phone, and 
is sensitive to change. It can be completed in 5-8 minutes and has a reported grade 
six reading level, and has good psychometric properties (Esper et al., 1997). The 
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general scale is valid and reliable in adults in general, in people older than 65, and in 
rural populations. 
In order to increase the reliability of the survey it was pre-tested by eight 
people in total: three cancer survivors, two cancer advocates and three researchers. 
The survey was created at a grade eight reading level. 
3.2. Recruitment 
Initially, we had planned to recruit men with prostate cancer through prostate 
cancer support groups, the prostate cancer retreat, and cancer clinics. However, we 
were unable to recruit many patients from the cancer clinic (see section 3.2.3 A-
Recruitment, Cancer Clinics), and had very few men who were undergoing active 
treatment in our study. Therefore, we decided to conduct a mailed survey of men 
with prostate cancer who had been diagnosed within the previous two years of the 
survey. 
3.2.1.Support groups 
Six of the seven prostate cancer support groups across the province 
participated in the study: St. John's, Gander/Kittiwake, Grand Falls-Windsor, Trinity 
North, Trinity South, and Corner Brook Western. The Labrador group was on hiatus 
when support groups were contacted and did not take part in the study. 
Each group leader was contacted to discuss the study and how to facilitate the 
distribution of individual surveys to support group participants. Each group leader 
was then sent a survey kit which contained individual survey packages, instructions 
and background information, and a return courier envelope (see Appendices B,C). 
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Each individual survey package included a self-addressed, postage paid 
envelope for the participant to mail back the completed survey. Inside the envelope 
there was a cover sheet explaining the survey, the eight-page survey (four pages 
double sided), and a separate form to request a copy of the study report (and provide a 
mailing address for the report). 
The group leader distributed the individual survey packages in the support 
groups. The background information was included in the kit to aid the group leaders 
in describe the survey to support group members. The leader was asked to return 
undistributed surveys in the courier envelope in order to exclude undistributed 
surveys from the calculation of response rates 
Participants were encouraged to take the survey home with them, review the 
survey and complete the survey, while omitting any questions they did not feel 
comfortable in answering. Participants were asked to return completed surveys by 
mail in the self-addressed envelopes provided. Survey kits were mailed to support 
group facilitators in April and May of 2007. 
3.2.2. Cancer retreat 
The Prostate Cancer Support Group Network for Newfoundland and Labrador 
hosts an annual retreat at Mac Simms Camp outside of Grand Falls-Windsor. A 
research assistant attended the Fall 2007 (October 5-6th, 2007) retreat to explain the 
survey, answer any questions and distribute the survey packages to anyone who may 
not have previously received one through their own support group locations. 
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3.2.3. Cancer clinics 
Cancer patients were also recruited from four cancer clinics across the 
province: St. John's, Gander, Grand Falls-Windsor, and Comer Brook. Several 
different methods were used to distribute surveys in the cancer clinics. These methods 
were tailored to the preferences of the clinic staff at each site. 
In central Newfoundland, a research assistant visited the clinic in Grand Falls-
Windsor for two days and the Gander clinic for one day. Clinic nursing staff acted as 
points of contact, informing patients of the study and referring interested participants 
to the research assistant for a survey package. Patients had the choice to complete the 
survey package on site and return in to the research assistant, or take it home to 
complete (and return by mail) in the self-addressed envelopes enclosed in the survey 
package. 
In Comer Brook, surveys were mailed out to the nursing staff who agreed to 
inform prostate cancer patients of the study and distribute surveys to willing 
participants. 
In St. John's, a number of methods were used to recruit patients from the 
cancer clinic. Initially, at the medical oncology clinics, registration clerks were asked 
to inform patients of the study and refer interested participants to the research 
assistant for a survey package5• The research assistant was available in the waiting 
area of the clinic. However, the registration clerks were unwilling to inform patients 
about the study (and did not want a research assistant in the waiting room) so boxes 
were placed at both clinic registration desks along-side a poster (Appendix E) which 
5 In order to protect patient privacy the ethics committee required that we did not directly contact 
patients. 
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introduced the study. Interested patients could pick up a copy from the box and 
return completed surveys in the return slot in the box. The survey boxes were 
checked on a regular basis for completed survey packages. 
At the radiation clinic, staff agreed to inform each prostate cancer patients of 
the study as they came in for treatment. Survey packages were provided to the 
radiation clinic and were given to patients visiting the clinic for the first time. 
Patients were recruited from the cancer clinics from June to September 2007. 
3.2.4.Urology clinics 
Information about the study was provided in urology and general surgery 
clinics at the Health Sciences Centre and St. Clare's Hospital through the posters 
advertising the study. The posters provided brief information about the study and 
encouraged individuals interested in participating to contact the research assistant for 
a survey package. There were no contacts solicited through this method and therefore 
no surveys were distributed by this method. 
3.2.5. Mailed survey 
Because we were unable to recruit many patients from the cancer clinics, we 
did not have a large number of men in our sample who had been diagnosed recently 
(less than one year) with prostate cancer. Therefore, we decided to conduct a mailed 
survey of men who had been diagnosed with prostate cancer within the preceding two 
years. 
The Newfoundland and Labrador Cancer Registry provided the names and 
mailing addresses of men who had been diagnosed with prostate cancer over a year 
and a half period, dating back to January 2007. In order to comply with privacy 
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requirements, the data were provided to a third party (Ms Sarah Wickham) who 
prepared mailing labels and mailed the survey packages. Only Ms. Wickham had 
access to names of individual patients. 
For the mail-out, we modified the survey packages by including a letter that 
explained that the patients name and address had been identified through the Cancer 
Registry and that this information would be kept confidential and not linked to their 
individual survey responses . The letter included was signed by thesis supervisor, Dr. 
Maria Mathews (Appendix A). 
The survey was mailed during the last week of January 2008. Because of 
costs, we only mailed one survey to each individual, with no further follow-up. To 
increase response rates, we raised awareness of the study through the media. The 
study was discussed on CBC radio noon, in a news release to all media, VOCM 
website and radio station, as well as the Rogers Television cable roll-up for a period 
of one month. Cable roll-ups are ads or public service announcements run only in 
text on local community cable channels. 
3.3. Eligibility 
To be eligible for the study, men must have been 19 years of age or older, 
understand English, reside in Newfoundland and Labrador, not be enrolled in a 
clinical trial, and have returned their survey by April 30,2008. Men who had 
previously been diagnosed with cancer were excluded from the study because they 
may have had different costs due to their previous diagnosis. Eligibility was assessed 
through a number of questions posed in the survey itself, such as birth date and 
whether they were receiving treatment for another form of cancer and taking part in a 
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clinical trial. Patients in clinical trails were excluded since some of their costs may 
have been covered by the trail. Surveys received after April 30, 2008 were not 
included in the study. 
In addition, we excluded respondents who did not provide at least one of the 
following fields: income, community or postal code. These fields were used to 
calculate (or infer) proportion of income spent on OOP costs. For respondents who 
did not answer the income question, we used the postal code and/or community name 
to determine median household income (see section 3.5.5 Socio-demographic factors) 
Lastly we excluded any duplicate surveys. We identified duplicate surveys by 
creating a unique identifier from survey responses consisting of diagnosis year + last 
three digits of postal code + birth year. 
3.4. Data management 
The data were entered into a database using SPSS data entry software and 
analyzed using SPSS software. Data entry errors were identified using frequencies 
and cross-tabulations. Wherever possible, we consulted the original survey to correct 
responses. 
A code was developed to track response rate for surveys distributed for the 
various methods other than cancer registry mail-out. Before being mailed or handed 
out, surveys were coded with a code that indicated the town or community and the 
distribution method. Response rates were calculated for each community and 
distribution method by dividing the total number of returned surveys by the total 
number of surveys distributed to a given town and method. 
29 
3.5.Variables 
Based on survey responses, we created variables to describe OOP costs, 
coping strategies, attitudes, quality of life, socio-demographic characteristics, and 
clinical information. A complete list of all variables and their coding scheme is 
presented in Appendix F. 
3.5.1. Costs 
The question was designed to ask participants about all of the costs related to 
their cancer treatment that they paid for OOP. Based on a review of the literature 
(Mathews et al., 2009a; Longo et al., 2006; Lauzier et al., 2005; Cohn, 2003; Guidry 
et al., 1998; Moore, 1998; Moore, 1999), we inquired about costs relating to 
medications, travel and accommodations, supportive costs and any other costs a 
participant may have had related to their cancer treatment. In this study, respondents 
were asked to list costs for the last month as well as the last quarter (or three months). 
We used a limit of three months since recall beyond this time frame may not be 
reliable. We requested costs for the two time periods (one month and three months) 
because although recall would be greater for a one month period, the costs may vary 
substantially from month to month. While recall over a three month period may be 
less reliable, these figures may provide a more realistic picture of true costs. 
We grouped costs into three categories: 1) drugs and supportive costs, 2) 
travel costs, and 3) all costs. Drugs and supportive costs included the cost of 
prescription and over-the-counter drugs, complementary and alternative medications, 
and supplies (eg. bandages, incontinence supplies). Travel costs included 
transportation (all forms), lodging (all forms), meals and parking. "All Costs" 
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included the costs included under drug and supportive costs, the costs listed as travel 
costs, and costs associated with an escort, communication costs (e.g. phone) and child 
or elder care. Costs for each category were calculated by adding the costs reported 
for each relevant category. Costs were calculated for a one month period as well as a 
three month period or 'quarter'. 
We created two sets of variables to examine costs: actual values and 
proportion of income consumed by OOP costs. Actual values were grouped into 
three categories: $0, $0.01-499.99, or $500 or more. These cut-offs were determined 
by the frequencies of respondents in each group. 
The proportion of quarterly income consumed by costs was calculated by 
dividing each of the three costs categories (drugs and supplies, travel, and all costs) 
by quarterly income. Annual income was mid-point income in each income category 
(e.g. $35,000 for $30,000 to $39,999). For the lowest and highest categories, $15,000 
and $75,000 were used, respectively. These values were divided by four to calculate 
quarterly income. 
Proportion of quarterly income consumed by costs was grouped into four 
categories which correspond with the eligibility criteria employed by the 
Newfoundland and Labrador Prescription Drug Program- Assurance Plan; 0, 0.01-
4.99%, 5.00-7.49%, 7.50-9.99% and 10.00% and more. (Government of 
Newfoundland and Labrador, 2007). Because of the limited number of respondents 
in each category, we regrouped the categories into three categories: 0, 0.01 -7.49% 
and, 7.50% and greater. 
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3.5.2. Coping Strategies 
A previous qualitative study of cancer patients in Newfoundland and Labrador 
(Mathews et al., 2009b) suggested that patients might employ coping strategies to 
deal with the high costs of medications and travel. In this study, we asked 
participants ten questions relating to the use of strategies to cope with the costs of 
both drugs and transportation to and from appointments or treatment. These 
questions used a five point Likert scale describing the frequency of use, where one 
was "never" and five was "all of the time". 
Due to the very small number of respondents who indicated they used any of 
these strategies, we grouped responses to these questions into two main variables: 
uses any drug related coping strategy and used any appointment related coping 
strategy. The categories were coded on a yes/no basis depending on whether or not 
any of the coping strategies had ever been used. For use of drug related coping 
strategies, the variable was coded as "yes" if respondents indicated any use ofthe 
strategies (answers 2-5 i.e.: "not very often", "some of the time", "most of the time" 
and "all of the time") for any of the following questions: 
• Spread out a medication over a longer period of time to make it last longer 
• Replaced the medication your doctor prescribed with another cheaper one 
• Skipped one or more dose of medication to save on costs 
• Bought only what you thought was the most important medication 
• Not filled a prescription because of the cost 
• Delayed filling a prescription because of the cost 
• Asked my doctor for free samples of a drug 
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For use of travel related coping strategies, the variable was coded as "yes" if 
respondents indicated any use of the strategies (answers 2-5 i.e.: "not very often", 
"some ofthe time", "most ofthe time" and "all of the time") for any ofthe following 
questions: 
• Spread out the time between visit to the doctor for follow-up visit 
• Missed or cancelled an appointment with the cancer clinic to save money 
• Missed or cancelled scheduled cancer treatment to save money 
3.5.3. Attitudes 
A series of questions were designed to determine patients' attitudes towards 
the OOP costs of the potential stressors associated with this. Ten questions used a 
five-point likert scale. Participants were asked to respond to each sub-question based 
on the five-point scale ranging from strongly disagree to strongly agree. The 
questions related to physicians knowledge of costs, stress caused by cost and attitudes 
towards the assistance and financial support offered for costs such as medications. 
The questions listed included: 
• My OOP costs influenced my decisions about how to treat my prostate cancer 
• My cancer doctor is aware of my OOP costs for my prostate cancer 
• My doctor takes costs into account when prescribing drugs for me 
• My cancer related costs create a lot of stress 
• Cancer costs create more stress for me than other sources of stress in my life 
• I am having trouble paying for my cancer costs 
• I am aware of assistance programs to help me with cancer costs 
• All prescription drugs should be free to people with low income 
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• Assistance programs are well advertised. 
Because the responses to the questions were highly skewed, the responses to 
each item were collapsed into two categories: agreed (which included the responses 
"agree" and "strongly agree") and disagreed (which included the responses "strongly 
disagree", "disagree" and "neither agree nor disagree") 
3.5.4. Quality of Life 
We used the Functional Assessment of Cancer Therapy general scale (FACT-
G) and the prostate subscale (FACT-P) in order to determine respondents' quality of 
life. Scores for the FACT-G and FACT-P scales were calculated according to 
detailed instructions provided by the originators of the scale (Cella, 2006). Generally, 
a higher score indicates a higher quality of life. 
3.5.5. Socio-demographic Characteristics 
3.5.5.1. Age: 
Age was calculated by subtracting the birth date from the year and month 
when the survey was completed. Once age was determined, participants were grouped 
into two age categories: less than 65 years of age and 65 years of age and older. This 
grouping was based on the cutoff for senior citizens, benefits (such as the 65 Plus 
drug insurance plan). 
3.5.5.2. Community type 
Community type was grouped as either urban or rural. Urban centres had 
populations of greater than 10,000 such as St. John's, Mount Pearl, Gander, Grand 
Falls-Windsor, Comer Brook and Conception Bay South (CBS) and their bedroom 
communities. All of these communities except for CBS and Mount Pearl have cancer 
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clinics. CBS and Mount Pearl are within one hour driving distance to St. John's. 
Rural communities had populations less than I 0,000 and were more than one hour 
from the nearest cancer clinic. Driving times were determined by road distance 
through an online map program (Google maps, n.d.). 
3.5.5.3. Marital status 
Marital status was grouped into two categories: partnered or unpartnered. The 
"partnered" category included married or living with partner. The "unpartnered" 
category included single-never married, single-divorced or separated, and widower. 
The survey question was based on the questions included in the 2007 Canadian 
Community Health Survey (Statistics Canada, 2007b ). 
3.5.5.4. Dependents 
This variable described the number of children or elderly relatives in the care 
of the respondent. The survey asked respondents to indicate whether they had 
dependents and if so, the number of children and/or elderly relatives, for whom they 
cared. 
3.5.5.5. Employment status 
Employment status was originally reported with ten categories (full time, part 
time, self-employed, seasonal/employment insurance, paid sick leave, long term 
disability, unemployed, semi-retired, retired, other). Because a large number of 
respondents self-identified as 'retired', the original ten categories were re-grouped 
into the following four categories: full-time or self-employed, part-time or semi-
retired, seasonal, sick leave, unemployed or other, and retired. The survey question 
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was based on the questions included in the 2007 Canadian Community Health Survey 
(Statistics Canada, 2007b ). 
3.5.5.6. Education 
We regrouped responses into five categories. Less than high school, 
completed high school, did some community college, technical school or university, 
some post secondary, completed post secondary, graduate/professional degree. The 
survey question was based on the questions included in the 2007 Canadian 
Community Health Survey (Statistics Canada, 2007b ). These categories were also 
used in a previous study on OOP in Newfoundland and Labrador (Mathews & Basky, 
2004). 
3.5.5.7.Income 
The survey asked respondents to indicate their annual household income (pre 
tax) by checking one of eight categories ranging from less than $9,999 to greater than 
$70,000. Each category increased in increments of $10,000. The survey question was 
based on the questions included in the 2007 Canadian Community Health Survey 
(Statistics Canada, 2007b ). 
In order to limit missing data, we used the median income of the respondent's 
community if the respondents had not indicated their income (10.5% of respondents 
did not complete the income question). If respondents did not identify a community 
of residence, their postal code was used to identify their community (using the 
Canada Post Website), (Canada Post, 2008). Once the community was determined, 
the median annual income was retrieved from the Government ofNewfoundland and 
Labrador Community Accounts website (Community Accounts, 2008). 
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We regrouped income into seven categories. We combined the lower two 
categories; less than $10,000 and $10,000 to $19,999 into the category less than 
$19,999 due to smaller numbers in the original two categories. 
3.5.5.8. Private insurance 
This variable was coded based on the yes/no response. 
3.5.5.9. MTAP 
Upon consultation with cancer advocates from the Canadian Cancer Society, a 
question regarding the Newfoundland and Labrador provincial government's Medical 
Transportation and Assistance Program (MTAP) was added to the survey. The 
question asked participants about their knowledge ofMTAP and a whether they had 
applied or were planning to apply to the program. Previous research (Mathews& 
Basky, 2003) had shown that few patients were aware of the travel subsidy. 
3.5.6. Clinical characteristics 
3.5.6.1.Time since diagnosis 
Time since diagnosis was based on the month and year and calculated into a 
number (of months) based on the date of survey collection (summer 2007 for support 
group and clinic delivered surveys, January 2008 for mail-out surveys). The number 
of months was re-coded into four categories: 0-6 months, 7-12 months, 13-24 months, 
and more than 24 months. 
3.5.6.2. Current treatment 
Participants were asked to list all treatments they were receiving for their 
prostate cancer, if any, at the time they completed the survey. The treatments listed 
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were: radiation, chemotherapy, hormonal treatment, surgery- specify, and no active 
treatment follow-up. An area to list "other" treatments was also available. 
3.5.6.3. Previous treatment 
Respondents were also asked to indicate any form of treatment they had 
received previously for their prostate cancer. Previous treatments listed on the survey 
were: radiation, hormonal therapy, chemotherapy, surgery (prostatectomy, 
transurethral resection of the prostate (TURP) orchiectomy, other), as well as a space 
to identify "other" treatment previously received. 
3.5.6.4. Length oftime receiving treatment 
Respondents were asked to indicate the length of time they had been receiving 
treatment. The categories listed on the survey were: less than 3 months, 3-6 months, 
between 6 months and one year. 
3.5.6.5. Drugs taken 
Respondents were asked to list any drugs they were currently taking as a 
result oftheir prostate cancer. Based on responses to this open-ended question, the 
drugs were then coded into four groups on a yes/no basis. A medical oncologist was 
consulted regarding the appropriateness of the groupings and assignments of listed 
medications to the determined categories: Vitamins, Hormonal, Supportive, and Other 
(Appendix G). 
3.6. Statistical Analysis 
To assess the representativeness of the sample, we compared community type 
and age of respondents to data obtained from the Cancer Registry. Using chi square 
tests, we compared the proportion of men from urban and rural communities in the 
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sample frame and the sample. Rural was defined as communities with less than 
10,0000 and one hour (driving distance) or more from an urban centre. To compare 
age, we obtained the age of incidence for prostate cancer for the province for 2004-
2008 (Personal Communication Ms Susan Ryan, Manager Newfoundland and 
Labrador Cancer Registry, January 5, 2010). 
We used frequencies (for categorical variables) and means and standard 
deviations (for continuous variables) to describe the characteristics of the sample. 
For research objective one (to identify the types and magnitude of OOP costs 
incurred by prostate cancer patients), we used frequencies to describe the amount of 
OOP costs and proportion of income consumed by OOP cancer care costs. 
For research objective two (to describe patients' strategies to manage OOP 
costs for prostate cancer care), we used frequencies to describe the number of patients 
in our sample who used any drug or appointment related cost saving strategy. 
For research objective three, (to determine whether OOP costs affect patient's 
cost management strategies, attitudes, quality of life), we used chi-square tests to 
identify examine differences in the use of costs management strategies and attitudes 
by patients with different OOP costs (total amount and proportion of income 
consumed by OOP costs). We used ANOVA to identify differences in quality oflife 
scores (FACT-G and FACT-P) among patients with different OOP costs. 
For research objective four (to examine differences between urban and rural 
prostate cancer patients in the types and amounts ofOOP, costs management 
strategies, attitudes, and quality of life), we used chi square tests (for categorical 
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variables) categorical and ANOVA (for continuous variables) to compare urban and 
rural patients. 
We did not use multivariable statistics because we did not find significant 
differences between the independent variable (costs and urban/rural) and the main 
dependant variables (use of cost saving strategies, attitudes, and quality oflife). 
3. 7. Ethical Considerations 
The Human Investigations Committee of Memorial University approved this 
study (Appendix H). The study was also approved by the institutional review board 
of the Eastern Regional Integrated Health Authority and the cancer clinic's scientific 
advisory committee (Appendices I, J). An amendment to include the mail out survey 
as part ofthe study protocol was approved by the Human Investigations Committee 
of Memorial University ofNewfoundland in December 2007 (Appendix K). 
In order to protect confidentiality, data are presented in aggregate only. No 
individuals are identified in any report or presentation. Moreover when surveys were 
administered in group settings, we asked all group members to take a survey but to 
return an incomplete survey if they chose not to take part in the study. For the 
mailed survey, names of prostate cancer patients were provided to a trusted third 
party so that study investigators would not be able to connect responses to individual 
names. 
All participants were offered a summary of the study findings by completing a 
form and returning it with their survey. The forms were separated from the survey 
upon receipt and no identifying markers were made to the surveys which would make 
it possible to link the contact information to the survey responses. 
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All data were stored in a secure room. Only the researcher (Emma Housser) 
and supervisor (Maria Mathews) had access to the data. Files were password 
protected. 
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Chapter 4: Results 
4.1 Response rates 
Response rates are presented in Table 4.1. The table describes the community 
where surveys were distributed, method of distribution, and the number of surveys 
distributed and returned. A response rate is given for each location of distribution 
and further broken down into the method of distribution used. The overall response 
rate was 27.21%. 
Table 4.1 Survey Response Rates by method and location. 
Survey response rates 
Location Method Returned Distributed Response Rate 
(%) 
St. John's Clinic 11 42 26.19 
Gander Clinic 1 7 14.29 
Grand Falls- Clinic 4 6 66.67 
Windsor 
Comer Brook Clinic 3 35 8.57 
Total clinic 19 90 21.11 
St. John's Support group 19 41 46.34 
GFW Support group 7 17 41.18 
Gander Sttpport group 6 6 100.00 
Western- Comer Support group 10 25 40.00 
Brook 
Trinity North Support group 5 20 25.00 
Trinity South Support group 1 25 4.00 
Total Support 48 134 35.00 
group 
Grand Falls- Prostate cancer 3 50 6.00 
Windsor retreat 
NL Cancer Registry 139 494 26.72 
Mail out 
Total: 209 768 27.21 
A total of 768 surveys were distributed and 209 surveys were returned. As 
shown in Table 4.2, 39 surveys were excluded from the study because they were 
received after the study close date of April 301\ 2008, or because respondents had a 
previous cancer diagnosis, were receiving treatment for another form of cancer, were 
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taking part in a clinical trial, were not residents of Newfoundland and Labrador, or 
did not provide income (or community or postal code which were used to infer 
income). The final study sample consisted of 170 respondents. 
Table 4.2 Reasons for excluding returned surveys. 
Excluded from Analysis (n=39) n (%) 
Received after data collection closed 7 (17.95) 
Previous cancer diagnosis 14 (35.90) 
Current treatment for other cancer 4 (10.26) 
Clinical Trial 8 (20.51) 
No income given (no town listed) 1 (2.56) 
No community (or postal code given) 4 (10.26) 
Not NL resident 1 (2.56) 
4.1.1 Sample Size 
Given our sample of 170 respondents, we can detect a difference of 3.9 points 
between urban and rural men and the quality oflife score using the FACT-P 
instrument using a two-tail test with a power of0.8 (Lenth, 2006-9). We used the 
FACT-P instrument to assess sample size because it is the only outcome measure that 
has had extensive testing and reported means and standard deviations. FACT-P has a 
mean of67 and standard deviation of8.7 (Esper et al., 1997). 
4.1.2 Representativeness of the Sample 
To assess the representativeness ofthe sample, we compared community type and 
age of respondents to data obtained from the Cancer Registry. As shown in Table L1 
(Appendix L), the sample is representative in terms of community type and age of 
incidence. 
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4.2 Characteristics of the sample 
Table 4.3 describes the demographic characteristics of the sample of men in this 
study. The majority of the survey sample is made up of senior citizens, 61.2% were 
65 years old or greater. Urban residents made up a slight majority (54.1 %) over rural 
(45.9%) respondents. The sample was largely married or "partnered" (87.9%). 
Retirement was the most frequently indicated choice for employment status with 
72.4% falling into this category. Roughly one third of the sample (33.7%) had less 
than a high school education, The two most frequently indicated income categories 
were $20,000 to $29,999 and $30,000 to $39,999, which made up 41.8% of the 
sample (22.4% and 19.4% respectively). The majority of the sample had some form 
of private insurance (64.6%) but had never heard about the provincial government's 
Medical Transportation Assistance Program (59.7%). 
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Table 4.3 Demographic characteristics of study participants. 
Characteristic n (%) 
Age (n = 170) 
<65 66 (38.8) 
>65 104 (61.2) 
Community Type (n = 170) 
Urban 78 (45.9) 
Rural 92(54.1) 
Marital Status (n = 165) 
Un-partnered 20(12.1) 
Partnered 145 (87.9) 
Dependents (n = 164) 
Yes 32 (18.8) 
No 132 (77.2) 
Employment Status (n = 169) 
Full-Time/self-employed 18 (10.7) 
Part-Time/semi -retired 14 (8.3) 
Seasonal/sick leave/unemployed/other 14 (8.3) 
Retired 123 (72.4) 
Education (n = 166) 
Less than high school 56 (33.7) 
Completed high school 34 (20.5) 
Some post secondary 24 (14.5) 
Completed post secondary 30(18.1) 
Graduate/professional degree 22 (13.3) 
Income (n = 170) 
< $19,999 24 (14.1) 
$20,000 - $29,999 38 (22.4) 
$30,000 - $39,999 33 (19.4) 
$40,000 - $49,999 25 (14.7) 
$50,000 - $59,999 19 (11.2) 
$60,000 - $69,999 10 (5.9) 
> $70,000 21 (12.4) 
Have Private Insurance (n = 161) 
Yes 104 (64.6) 
No 57 (35.4) 
Know about MTAP (n = 139) 
Yes 56 (40.3) 
No 83 (59.7) 
The clinical characteristics of the survey sample are presented in Table 4.4 
Men were asked several questions about their current and past treatment. Clinical 
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information including time since diagnosis, any current or previous treatment 
received, length of time receiving treatment and a listing of drugs are presented. 
Table 4.4 Clinical Characteristics of study participants. 
Clinical Characteristics n (%) 
Time Since Diagnosis (n = 167) 
0-6 months 32 (19.2) 
7-12 months 58 (34.7) 
13 - 24 months 39 (23.4) 
24 months+ 38 (22.8) 
Current Treatment (n = 170) 
Radiation 19(11.2) 
Hormone Therapy 28 (16.5) 
Chemotherapy 0 (0) 
No Active Treatment 108 (63.5) 
Other 16 (9.4) 
Active Treatment or Follow-up 46(27.1) 
Past treatment (n = 169) 
Radiation 51 (30.2) 
Hormone Therapy 22 (12.9) 
Chemotherapy 1 (0.6) 
Surgery 85 (50.0) 
Prostatectomy 75 (44.1) 
TURP 3 (1.8) 
Orchiectomy 2 (1.2) 
Other 1 (0.6) 
Length of Time Receiving Treatment 
(n = 75) 
< 3 months 31 (41.3) 
3-6 months 12 (16.0) 
6 months- 1 year 32 (42.7) 
Drugs taken (n = 170) 
Hormone Treatment 
Yes 33 (19.4) 
No 137 (80.6) 
Supportive 
Yes 19(11.2) 
No 151 (88.8) 
Vitamins/Supplements 
Yes 13 (7.6) 
No 157 (92.4) 
Miscellaneous 
Yes 7 ( 4.1) 
No 163 (95.9) 
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The largest proportion of respondents had been diagnosed seven to 12 months 
before the survey. Almost two thirds ofthe sample (63.5%) were on no active 
treatment. However, in the past, half had some form of surgery, namely 
prostatectomy, while one third received radiation treatment. The variable length of 
time receiving treatment should be reviewed with a caution as there was no category 
given for treatment received for more than one year. Respondents whose treatment 
was 'watchful waiting' may not have answered this question. This confusion may be 
reflected by the low response rate for this particular question (n=75). For those 
responding to the question, there was a fairly even split between the categories less 
than three months and six months to one year (41.3% and 42.7% respectively). In 
terms of drug treatment, one fifth of the sample reported taking hormone treatments, 
(which corresponds closely with reports for current and previous treatments) 
Table 4.5 presents the OOP costs incurred by men in the study. Costs were 
listed for three categories, at two intervals. Costs were given for a one month time 
period, and a quarter (three months) for drugs and supplies costs, travel costs, and all 
costs which included the two former categories as well as costs for an escort to 
accompany the patient on medical visits. Appendix F presents a list of drugs included 
in the study). 
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Table 4.5 Out-of-pocket costs incurred by study participants in previous month and 
previous three months. 
Cost Costs incurred over Costs incurred over 
previous one month previous three months 
n (%) n (%) 
Drugs and Supplies (n = 170) 
$0 126 (74.1) 121 (71.2) 
$0.01 - $499.99 42 (24.7) 44 (25.9) 
>$500.00 2 (1.2) 5 (2.9) 
Travel (n = 170) 
$0 113 (66.5) 108 (63.5) 
$0.01 - $499.99 36 (21.2) 38 (22.4) 
>$500.00 21 (12.4) 24 (14.1) 
All Costs (n = 170) 
$0 95 (55.9) 91 (53.5) 
$0.01 - $499.99 51 (30.0) 47 (27.6) 
>$500.00 24 (14.1) 32 (18.8) 
For the "All Costs" category, almost one fifth (18.8%) reported high costs, 
(costs exceeding $500) over a period of three months, with the bulk of these costs 
stemming from travel. The vast majority of respondents however did not report any 
costs. Very few men reported high drug costs ($500 or more) in the previous month 
or previous quarter. 
We also considered costs as the percent of income consumed by out-of-pocket 
costs. The categories reflect cut-offs for the provincial drug subsidy program (Table 
4.6). For each of the three costs categories (Drugs and supplies, travel and all costs) 
most men reported no costs. A small proportion of men (3.5% -21.5%) reported high 
costs (costs consuming more than 7.5% of their monthly income). Roughly one in 
five men reported that cancer related costs (all costs) consumed 7.5% or more of their 
monthly income. When considered over a three month period, the proportion 
decreases slightly. Roughly one in nine participants reported that cancer related costs 
(all costs) consumed 7.5% or more of their quarterly income. 
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Table 4.6 Percent of monthly and quarterly (3 months) income consumed by OOP 
costs. 
% of Quarterly Income Consumed n (%) n (%) 
Drugs and Supplies (n = 170) 
0% 126 (74.1) 121 (71.2) 
0.01 - 7.49% 38 (22.4) 45 (26.5) 
>=7.50% 6 (3.5) 4 (2.4) 
Travel (n = 169) 
0% 113 (66.5) 108 (63.9) 
0.01 - 7.49% 25 (14.7) 42 (24.9) 
>=7.50% 32 (18.8) 19(11.2) 
All costs (n = 170) 
0% 95 (55.9) 91 (53.5) 
0.01 - 7.49% 39 (22.9) 52 (30.6) 
>=7.50% 36 (21.2) 12 (15.9) 
Table 4. 7 presents the use of cost related coping strategies as well as attitudes 
about cancer costs and subsidy programs. Although one fifth of men surveyed 
reported out-of-pocket costs in excess of $500 for a quarter, very few reported any 
use of either drug (8.2%) or appointment (3.5%) related coping strategy. 
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Table 4. 7 Use of Coping Strategies and Attitudes regarding OOP costs. 
Coping strategies 
Drug Coping Strategies (n = 170) 
Yes 
No 
Appointment Coping Strategies (n = 170) 
Yes 
No 
Attitude Questions 
My OOP costs influenced my decisions about how to treat 
my prostate cancer (n=125) 
Agree 
Disagree 
My cancer doctor is aware of my OOP costs for my prostate 
cancer (n=115) 
Agree 
Disagree 
My doctor takes costs into account when prescribing drugs 
for me (n=114) 
Agree 
Disagree 
My cancer related costs create a lot of stress (n = 121) 
Agree 
Disagree 
Cancer costs create more stress for me than other sources of 
stress in my life (n= 122) 
Agree 
Disagree 
I am having trouble paying for my cancer costs (n=120) 
Agree 
Disagree 
I am aware of assistance programs to help me with cancer 
costs (n=121) 
Agree 
Disagree 
All prescription drugs should be free to everyone, regardless 
of their income (n=127) 
Agree 
Disagree 
All prescription drugs should be free to people with low income 
(n=131) 
Agree 
Disagree 
Assistance programs are well advertised (n= 132) 
Agree 
Disagree 
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n (%) 
14 (8.2) 
156 (91.8) 
6 (3.5) 
164 (96.5) 
9 (7.2) 
116 (92.8) 
31 (27.0) 
84 (73.0) 
15 (13.2) 
99 (86.8) 
33 (27.3) 
88 (72.7) 
26 (21.3) 
96 (78.7) 
15 (12.5) 
105 (87.5) 
33 (27.3) 
88 (72.7) 
78 (61.4) 
49 (38.6) 
110 (84.0) 
21 (16.0) 
17 (12.9) 
115 (87.1) 
A small proportion of men (7 .2%) said that costs influenced their treatment 
decisions. The majority of respondents indicated that their doctor was not aware of 
their OOP costs related to prostate cancer (73.0%) and did not take costs into account 
when prescribing drugs (86.8%). More than one quarter of the men surveyed 
reported that cancer related costs were causing stress (27.3%), and roughly one fifth 
agreed that cancer costs caused more stress than other sources of stress (21.3%). One 
in eight respondents (12.5%) were having trouble paying for their cancer related 
costs. Most men were not aware of assistance programs (72.7%) and thought they 
were not well advertised (87 .1% ). The majority of participants agreed that all 
prescription drugs should be free to everyone, regardless of income (61.4%); 84% 
agreed that all prescription drugs should be free to people with low income. 
Quality of life scores, based on the Functional Assessment of Cancer Therapy 
are presented in Table 4.8. Functional Assessment of Cancer Therapy scores are 
reported for the overall quality oflife which can be compared across a diverse group 
of patients (FACT G Total) while the FACT P Total further narrows down the overall 
quality of life to prostate cancer. 
Table 4.8 Quality of life - Functional Assessment of Cancer Therapy- General, 
Prostate 
Quality of Life mean (std. dev.) 
FACTG Total (n = 126) 
Actual Range 49-108 84.97 (13.96) 
Theoretical Range 0-1 08 
FACT P Total (n=l26) 
Actual Range 58-147 117.17 (19.03) 
Theoretical Range 0-156 
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The higher the score, the better the quality of life. Scores were prorated to 
account for missing data. The mean score for the overall FACT -G was 84.97, with a 
range from 49 to 1 08 (theoretical range of 0 to 1 08) while the mean score for the 
FACT -P was 117.17 with a range of 58 to 147 (theoretical range ofO to 156). 
4.3. Costs 
4.3.1. Dollar value of costs 
The next series of tables examine the relationship between costs incurred (in 
dollar value) and demographic and clinical characteristics, use of cost saving 
strategies, attitudes and quality of life. Costs for the last quarter are presented in this 
chapter. Tables examining costs in the previous one month are presented in 
Appendix M. 
Table 4.9 presents the cross tabulations and chi-square test results comparing 
the demographic characteristics and the three categories of costs incurred (in dollar 
amounts). There were no significant differences across the demographic variables 
and the dollar amount of out-of-pocket costs. 
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Table 4.9 Level ofOOP costs (dollar amount) for the "All Costs" category in a 
quarter (3 month period) and demographic characteristics. 
Characteristic $0 $0.01 -
$499.99 ~$500.00 
n (%) n (%) n (%) p value 
Age (n = 170) 
< 65 35 (38.5) 14 (29.8) 17 (53.1) 0.112 
> 65 56 (61.5) 33 (70.2) 15 (46.9) 
Community Type (n = 170) 
Urban 49 (53.8) 18 (38.3) 11 (34.3) 0.077 
Rural 42 (46.2) 29 (61.7) 21 (65.6) 
Marital Status (n = 165) 
Un-partnered 10(11.2) 5 (10.9) 5 (16.7) 0.699 
Partnered 79 (88.8) 41 (89.1) 25 (83.3) 
Dependents (n = 164) 
Yes 16(18.2) 8 (17.4) 8 (26.7) 0.546 
No 72 (81.8) 38 (82.6) 22 (73.3) 
Employment Status (n = 169) 
Full-Time/self-employed 10(11.1) 5 (10.6) 3 (9.4) 
Part-Time/semi-retired 7 (7.8) 4 (8.5) 3 (9.4) 0.404 
Seasonal/sick 6 (6.7) 2 (4.3) 6 (18.8) 
leave/unemployed/other 
Retired 67 (74.4) 36 (76.6) 2 (62.5) 
Education (n = 166) 
Less than high school 29 (33.0) 17 (36.2) 10 (32.3) 
Completed high school 16 (18.2) 12 (25.5) 6 (19.4) 0.828 
Some post secondary 16 (18.2) 3 (6.4) 5 (16.1) 
Completed post secondary 16 (18.2) 9 (19.1) 5 (16.1) 
Graduate/professional degree 11 (12.5) 6 (12.8) 5 (16.1) 
Income (n = 170) 
< $19,999 13 (14.3) 7 (14.9) 4 (12.5) 
$20,000- $29,999 19 (20.9) 12 (25.5) 7 (21.9) 
$30,000- $39,999 17 (18.7) 6 (12.8) 10 (31.2) 0.813 
$40,000 - $49,999 13 (14.3) 7 (14.9) 5 (15.6) 
$50,000 - $59,999 12 (13.2) 6 (12.8) 1 (3.1) 
$60,000- $69,999 4 (4.4) 4 (8.5) 2 (6.2) 
> $70,000 13 (14.3) 5 (10.6) 3 (9.4) 
Have Private Insurance (n = 161) 
Yes 58 (65.9) 27 (62.8) 19 (63.3) 0.928 
No 30 (34.1) 16 (37.2) 11 (36.7) 
Know about MTAP (n = 139) 
Yes 29 (43.3) 13 (31.7) 14 (45.2) 0.404 
No 38 (56.7) 28 (68.3) 17 (54.8) 
* Statistically significant: p<0.05 
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Table 4.10 displays the cross tabulations and chi-square test results comparing 
the clinical characteristics and the categories of costs incurred (in dollar amounts). 
Compared to patients with costs, a larger proportion of patients with no costs were 
not having active treatment (i.e. treatment was watchful waiting), had been receiving 
treatment for less than three months, were receiving neither hormone treatment, 
supportive drugs nor vitamins/supplements. 
Table 4.10 Level of OOP costs (dollar amount) for the All Costs category in a quarter 
(3 month period) and clinical characteristics. 
Clinical Characteristics $0 $0.01 -
$499.99 ?::$500.00 
n (%) n (%) n (%) p value 
Time Since Diagnosis (n = 167) 
0-6 months 15(17.0) 12 (25.5) 5 (15.6) 
7- 12 months 29 (33.0) 18 (38.3) 11 (34.4) 0.656 
13 - 24 months 20 (22.7) 10 (21.3) 9 (28.1) 
24 months+ 24 (27.3) 7 (14.5) 7 (21.9) 
Current Treatment (n = 170) 
Radiation 
Yes 8 (8.8) 7 (14.9) 4 (12.5) 0.540 
No 83 (91.2) 40 (85.1) 28 (87.5) 
Hormone Therapy 
Yes 11 (12.1) 10 (21.3) 7 (21.9) 0.254 
No 80 (87.9) 37 (78.7) 25 (78.1) 
Chemotherapy 
Yes 0(0.0) 0 (0.0) 0 (0.0) .a 
No 91(100.0) 47(100.0) 32(100.0) 
No Active Treatment 
Yes 25 (27.5) 23 (48.9) 14 (43.8) 0.029* 
No 66 (72.5) 24 (51.1) 18 (56.2) 
Other 
Yes 7 (7.7) 5 (10.6) 4 (12.5) 0.685 
No 84 (92.3) 42 (89.4) 28 (87.5) 
Active Treatment or Follow-up 
Yes 19 (20.9) 18 (38.3) 9 (28.1) 0.091 
No 72 (79.1) 29 (61.7) 23 (71.9) 
Past treatment (n = 169) 
Radiation 
Yes 26 (28.6) 12 (25.5) 13 (41.9) 0.269 
No 65 (71.4) 35 (74.5) 18 (58.1) 
Hormone Therapy 
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Yes 9 (9.9) 6 (12.8) 7 (21.9) 0.221 
No 82 (71.4) 41 (87.2) 25(78.1) 
Chemotherapy 
Yes 1 (1.1) 0 (0.0) 0 (0.0) 0.646 
No 90 (98.9) 47(100.0) 32(100.0) 
Surgery 
Yes 47 (51.6) 22 (46.8) 16 (50.0) 0.865 
No 44 (48.4) 25 (53.2) 16 (50.0) 
Prostatectomy 
Yes 39 (42.9) 22 (46.8) 14 (43.8) 0.906 
No 52 (57.1) 25 (53.2) 18 (56.3) 
TURP 
Yes 2 (2.2) 1 (2.1) 0 (0.0) 0.702 
No 89 (97.8) 46 (97.9) 32(100.0) 
Orchiectomy 
Yes 1 (1.1) 0 (0.0) 1 (3.1) 0.447 
No 90 (98.9) 47(100.0) 31 (96.9) 
Other 
Yes 0 (0.0) I (2.1) 0 (0.0) 0.268 
No 91 (100.0) 46 (97.9) 32(100.0) 
Length of Time Receiving 
Treatment (n = 75) 
< 3 months 16 (51.6) 8 (34.8) 7 (33.3) 0.015* 
3-6 months 2 (6.5) 2 (8.7) 8(38.1) 
6 months - 1 year 13 (41.9) 13 (56.5) 6 (28.6) 
Drugs taken (n = 170) 
Hormone Treatment 
Yes 7 (7.7) 15(31.9) 11 (34.4) 0.000* 
No 84 (92.3) 32 (68.1) 21 (65.6) 
Supportive 
Yes 5 (5.5) 9 (19.1) 5 (15.6) 0.037* 
No 86 (94.5) 38 (80.5) 27 (84.4) 
Vitamins/Supplements 
Yes 2 (2.2) 8 (17.0) 3 (9.4) 0.007* 
No 89 (97.8) 39 (83.0) 29 (90.6) 
Miscellaneous 
Yes 3 (3.3) 3 (6.4) 1 (3 .1) 0.655 
No 88 (96.7) 44 (93.6) 31 (96.9) 
* Statistically significant; p<0.05 
a. No statistics available as variable is a constant in this instance. 
Table 4.11 displays the cross tabulations and chi-square test results comparing 
the use of coping strategies and the categories of costs incurred (in dollar amounts). 
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The proportion of men who used a drug coping strategy increased with total amount 
of costs. 
Table 4.11 Level of OOP costs (dollar amount) for the All Costs category in a quarter 
(3 month period) and use of coping strategies. 
Coping strategies $0.01 -
$0 $499.99 ::::$500.00 
n(%) n(%) n (%) p value 
Drug Coping Strategies 
(n=170) 
Yes 3 (3.3) 5 (10.6) 6 (18.8) 0.019* 
No 88 (96.7) 42 (89.4) 26 (81.2) 
Appointment Coping Strategies 
(n = 170) 
Yes I (1.1) 3 (6.4) 2 (6.2) 0.183 
No 90 (98.9) 44 (93.6) 30 (93.8) 
* Statistically significant; p<0.05 
As shown in table 4.12, there were no differences in quality oflife scores 
based on costs incurred (in dollar amounts). 
Table 4.12 Level of OOP costs (dollar amount) for the All Costs category in a quarter 
(3 th · d) d n f rti mon peno an qua 1 yo 1 e. 
Quality of Life $0 $0.01 - $499.99 2::$500.00 p value 
mean (sd) mean (sd) mean (sd) 
FACTG Total 
(n = 126) 
86.56 (14.597) 84.83(12.077) 81.00(15.208) 0.267 
FACT P Total 
(n=126) 119.87(19.813) 116.60( 17 .436) 111.04(18.953) 0.162 
* Statistically significant; p<0.05 
Table 4.13 displays the cross tabulations and chi-square test results comparing 
attitudes regarding costs and the level of income consumed by OOP costs. There were 
no significant differences. 
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Table 4.13 Level of OOP costs (dollar amount) for the All Costs category in a quarter 
(3 month period) and attitudes regarding these costs 
Attitudes $0 $0.01 - ~$500.00 
n (%) $499.99 n (%) p value 
n(%) 
OOP costs influenced 
treatment decisions 
Agree 3 (5.8) 2 ( 4.4) 4 (14.3) 0.250 
Disagree 49 (94.2) 43 (95.6) 24 (85.7) 
Doctor aware of my OOP 
costs 
Agree 15 (31.9) 9 (21.4) 7 (26.9) 0.538 
Disagree 32(68.1) 33 (78.6) 19 (73.1) 
Doctor takes costs into 
account 
Agree 9 (20.0) 4 (9.3) 2 (7.7) 0.214 
Disagree 36 (80.0) 39 (90.7) 24 (92.3) 
Cancer costs create a lot of 
stress 
Agree 11 (22.9) 9 (20.5) 13 (44.8) 0.050 
Disagree 37 (77.1) 35 (79.5) 16 (55.2) 
Cancer costs more stressful 
than other things 
Agree 9 (18.4) 8 (18.2) 9 (31.0) 0.342 
Disagree 40 (81.6) 36 (81.8) 20 (69.0) 
Trouble paying for my 
cancer costs 
Agree 3 (6.2) 6 (13.6) 6 (21.4) 0.149 
Disagree 45 (93.8) 38 (86.4) 22 (78.6) 
Aware of assistance 
programs 
Agree 15 (29.4) 10 (22.7) 8 (30.8) 0.692 
Disagree 36 (70.6) 34 (77.3) 18 (69.2) 
Prescription drugs free to 
everyone 
Agree 39 (70.9) 23 (53.5) 16 (55.2) 0.157 
Disagree 16 (29.1) 20 (46.5) 13 (44.8) 
Prescription drugs free to 
low income people 
Agree 49 (86.0) 40 (88.9) 21 (72.4) 0.146 
Disagree 8 (14.0) 5(11.1) 8 (27.6) 
Assistance programs are 
well advertised 
Agree 8 (13.3) 6 (14.0) 3 (10.3) 0.895 
Disagree 52 (86.7) 37 (86.0) 26 (89.7) 
* Statistically significant; p<0.05 
57 
4.3.2 Proportion oflncome consumed by costs 
The next series of tables examine the relationship between proportion of 
income consumed by OOP costs, demographic and clinical characteristics, use of cost 
saving strategies, attitudes and quality of life. Costs for the last quarter are presented 
in this chapter. Tables examining costs in last month are presented in Appendix M. 
Table 4.14 displays the cross tabulations and chi-square test results comparing 
the socio-demographic characteristics and proportion of income consumed by OOP 
costs. There were no significant differences. 
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Table 4.14 Percent of income consumed by OOP All costs category in a quarter (three 
mon th . d) d d h" h t . f peno an emogr_apJ IC c arac ens 1cs. 
Characteristic 0.01-
0% 7.49% ~7.50% 
n(%) n(%) n(%) p value 
Age (n = 170) 
< 65 35 (38.5) 18 (34.6) 13 (48.1) 0.501 
> 65 56 (61.5) 34 (65.4) 14 (51.9) 
Community Type (n = 170) 
Urban 49 (53.8) 20 (38.5) 9 (33.3) 0.075 
Rural 42 (46.2) 32 (61.5) 18 (66.7) 
Marital Status (n = 165) 
Un-partnered 10(11.2) 5 (9.8) 5 (20.0) 0.411 
Partnered 79 (88.8) 46 (90.2) 20 (80.0) 
Dependents (n = 164) 
Yes 16 (18.2) 9 (18.0) 7 (26.9) 0.582 
No 72 {88.8) 41 (82.0) 19 (73.1) 
Employment Status (n = 169) 
Full-Time/self-employed 10(11.1) 6 (11.5) 2 (7.4) 
Part-Time/semi-retired 7 (7.8) 4 (7.7) 3 (11.1) 0.968 
Seasonal/sick 6 (6.7) 5 (9.6) 3 (11.1) 
leave/unemployed/other 
Retired 67 (74.4) 37 (71.2) 19 (70.4) 
Education (n = 166) 
Less than high school 29 (33.0) 18 (34.6) 9 (34.6) 
Completed high school 16 (18.2) 12 (23.1) 6 (23.1) 0.666 
Some post secondary 16(18.2) 6 (11.5) 2 (7.7) 
Completed post secondary 16 (18.2) 11 (21.2) 3 (11.5) 
Graduate/professional degree 11 (12.5) 5 (9.6) 6 (23.1) 
Income (n = 170) 
< $19,999 13 (14.3) 6 (11.5) 5 (18.5) 
$20,000 - $29,999 19 (20.9) 10 (19.2) 9 (33.3) 
$30,000 - $39,999 17 {18.7) 10 (19.2) 6 (22.2) 0.722 
$40,000- $49,999 13 (14.3) 8 (15.4) 4 (14.8) 
$50,000 - $59,999 12 (13.2) 7 (13.5) 0 (0.0) 
$60,000 - $69,999 4 (4.4) 5 (9.6) 1 (3.7) 
> $70,000 13 (14.3) 6 (11.5) 2 (7.4) 
Have Private Insurance (n = 161) 
Yes 58 (65.9) 32 (66.7) 14 (56.0) 0.618 
No 30 (34.1) 16 (33.3) 11 (44.0) 
Know about MTAP (n = 139) 
Yes 29 (43.3) 15 (32.6) 12 (46.2) 0.417 
No 38 (56. 7) 31 (67.4) 14 (53.8) 
* Statistically significant; p<0.05 
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Table 4.15 displays the cross tabulations and chi-square test results comparing 
the clinical characteristics and proportion of income consumed by OOP costs. 
Compared to patients with costs that consumed any amount of their income, a larger 
proportion of patients without costs were not having active treatment (i.e. treatment 
was watchful waiting), and were receiving neither hormone treatment, supportive 
drugs nor vitamins/supplements. 
Table 4.15 Percent of income consumed by OOP All costs category in a quarter (three 
month period) and clinical characteristics. 
Clinical Characteristics 0.01-
0% 7.49% ~7.50% 
n(%) n(%) n(%) I! value 
Time Since Diagnosis (n = 167) 
0-6 months 15 (17.0) 14 (26.9) 3(11.1) 
7-12 months 29 (33.0) 20 (38.5) 9 (33.3) 0.356 
13 - 24 months 20 (22.7) 10(19.2) 9 (33.3) 
24 months+ 24 (27.3) 8 (15.4) 6 (22.2) 
Current Treatment (n = 170) 
Radiation 
Yes 8 (8.8) 7 (13.5) 4 (14.8) 0.561 
No 83 (91.2) 45 (86.5) 23 (85.2) 
Hormone Therapy 
Yes 11 (12.1) 11 (21.2) 6 (22.2) 0.253 
No 80 (87.9) 41 (78.8) 21 (77.8) 
Chemotherapy 
Yes 0 (0.0) 0 (0.0) 0 (0.0) .a 
No 91(100.0) 52(100.0) 27(100.0) 
Active Treatment 
Yes 25 (27.5) 23(44.2) 14 (51.9) 0.026* 
No 66 (72.5) 29 (55.8) 13 (48.1) 
Other 
Yes 7 (7.7) 5 (9.6) 4 (14.8) 0.537 
No 84 (92.3) 47 (90.4) 23 (85.2) 
Active Treatment or Follow-up 
Yes 19 (20.9) 18 (34.6) 9 (33.3) 0.149 
No 72 (79.1) 34 (65.4) 18 (16.7) 
Past treatment (n = 169) 
Radiation 
Yes 26 (28.6) 13 (25.0) 12 (46.2) 0.141 
No 65 (71.4) 39 (75.0) 14 (53.8) 
Hormone Therapy 
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Yes 9 (9.9) 7 (13.5) 6 (22.2) 0.243 
No 82 (90.1) 45 (86.5) 21 (77.8) 
Chemotherapy 
Yes 1 (1.1) 0 (0.0) 0 (0.0) 0.646 
No 90 (98.9) 52(100.0) 27(100.0) 
Surgery 
Yes 47 (51.6) 25 (48.1) 13 (48.1) 0.899 
No 44 (48.4) 27 (51.9) 14 (51.9) 
Prostatectomy 
Yes 39 (42.9) 25 (48.1) 11 (40.7) 0.773 
No 52 (57.1) 27 (51.9) 16 (59.3) 
TURP 
Yes 2 (2.2) 1 (1.9) 0 (0.0) 0.744 
No 89 (97.8) 51 (98.1) 27(100.0) 
Orchiectomy 
Yes 1 (1.1) 0 (0.0) 1 (3.7) 0.349 
No 90 (98.9) 52(1 00.0) 26 (96.3) 
Other 
Yes 0 (0.0) 0 (0.0) 1 (3.7) 0.070 
No 91 (100.0) 52(100.0) 26 (96.3) 
Length of Time Receiving 
Treatment 
(n = 75) 16 (51.6) 8 (33.3) 7 (35.0) 0.054 
< 3 months 2 (6.5) 3 (12.5) 7 (35.0) 
3-6 months 13 (41.9) 13 (54.2) 6 (30.0) 
6 months - 1 year 
Drugs taken (n = 170) 
Hormone Treatment 
Yes 2 (2.2) 8 (15.4) 3(11.1) 0.013* 
No 89 (97.8) 44 (84.6) 24 (88.5) 
Supportive 
Yes 7 (7.7) 15 (28.8) 11 (40.7) 0.000* 
No 84 (92.3) 37 (71.2) 16 (59.3) 
Vitamins/Supplements 
Yes 5 (5.5) 9 (17.3) 5 (18.5) 0.041 * 
No 86 (94.5) 43 (82.7) 22 (81.5) 
Miscellaneous 
Yes 3 (3.3) 2 (3.8) 2 (7.4) 0.636 
No 88 (96.7} 50 (96.2) 25 (92.6) 
* Statistically significant; p<0.05 
a. No statistics available as variable is a constant in this instance. 
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Table 4.16 displays the cross tabulations and chi-square test results comparing 
the use of coping strategies and the categories of proportion of income consumed by 
OOP costs for a three month period. The proportion of patients who used a drug or 
appointment coping strategy increased with total proportion of income consumed by 
cancer related OOP costs. The proportion of patients who spent greater than 7.5% of 
their income on OOP cancer care costs and said they used drug coping strategies and 
appointment coping strategies was larger than the proportion of patients who did not 
spend any of their income on cancer related costs. 
Table 4.16 Percent of income consumed by OOP All costs category in a quarter (three 
month period) and use of coping strategies. 
Coping strategies 0% 0.01-7.49% :::7.50% 
n(%) n(%) n(%) p value 
Drug Coping Strategies 
(n = 170) 
Yes 3 (3.3) 5 (9.6) 6 (22.2) 0.007* 
No 88 (96.7) 47 (90.4) 2 (77.8) 
Appointment Coping 
Strategies (n = 170) 
Yes 1 (1.1) 2 (3.8) 3 (11.1) 0.046* 
No 90 (98.9) 50 (96.2) 24 (88.9) 
* Statistically significant; p<0.05 
There were no differences in quality of life scores and the proportion of 
income spent on out-of-pocket cancer related costs for a three month (Table 4.17) 
Table 4.17 Percent of income consumed by OOP All costs category in a quarter (three 
month period) and quality of life. 
Quality of Life 0% 0.01-4.99% :::7.49% p value 
mean (sd) mean (sd) mean (sd) 
FACTG Total 
(n = 126) 86.56 (14.597) 85.26 (11.631) 78.83 (16.318) 0.117 
FACT PTotal 
(n=126) 119.87 (19.813) 117.06 (16.906) 108.28 (19.813) 0.075 
.. 
* Statistically stgmficant; p<0.05 
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Table 4.18 displays the cross tabulations and chi-square test results attitudes and 
the categories of costs incurred (in dollar amounts). Compared to patients whose 
cancer costs consumed less than 7.5% of their income, a larger proportion of patients 
whose OOP cancer relate costs consumed more than 7.5% of their income agreed that 
cancer costs created a lot of stress, that cancer costs were more stressful than other 
things, and that they had trouble paying for their cancer costs. 
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Table 4.18 Percent of income consumed by OOP All costs category in a quarter (three 
month period) and attitudes regarding these costs. 
Attitudes 0% 0.01- ~7.50% p value 
n(%) 7.49% n(%) 
n(%) 
OOP costs influenced treatment 
decisions 
Agree 3 (5.8) 2 (4.1) 4 (16.7) 0.129 
Disagree 49 (94.2) 47 (95.9) 20 (83.3) 
Doctor aware of my OOP costs 
Agree 15 (31.9) 8 (17.4) 8 (37.4) 0.156 
Disagree 32 (68.1) 38 (32.6) 14 (63.6) 
Doctor takes costs into account 
Agree 9 (20.0) 3 (6.4) 3 (13.6) 0.154 
Disagree 36 (80.0) 44 (93.6) 19 (86.4) 
Cancer costs create a lot of stress 
Agree 11 (22.9) 8 (16.7) 14 (56.0) 0.001 * 
Disagree 37 (77.1) 40 (83.3) 11 (44.0) 
Cancer costs more stressful than 
other things 
Agree 9 (18.4) 5 (1 0.4) 12 (48.0) 0.001 * 
Disagree 40 (81.6) 43 (89.6) 13 (52.0) 
Trouble paying for my cancer costs 
Agree 3 (6.2) 5 (10.4) 7 (29.2) 0.018* 
Disagree 45 (93.8) 43 (89.6) 17 (70.8) 
Aware of assistance programs 
Agree 15 (29.4) 10 (20.8) 8 (36.4) 0.361 
Disagree 36 (70.6) 38 (79.2) 14 (63.6) 
Prescription drugs free to everyone 
Agree 39 (70.9) 25 (52.1) 14 (58.3) 0.139 
Disagree 16 (29.1) 23 (47.9) 10 (41.7) 
Prescription drugs free to low 
income people 
Agree 49 (86.0) 41 (83.7) 20 (80.0) 0.793 
Disagree 8 (14.0) 8 (16.3) 5 (20.0) 
Assistance programs well 
advertised 
Agree 52 (86.7) 41 (86.7) 22 (88.0) 0.986 
Disagree 8 (13.3) 6 (12.8) 3 (12.0) 
* Statistically significant; p<O.OS 
4.4. Urban versus Rural Residents 
In the next series of analyses, we compared urban and rural respondents. 
Table 4.19 compares the socio-demographic characteristics of urban and rural 
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respondents. Compared to urban residents, a larger proportion of rural residents had 
less than a high school education, earned less than $30,000 income, and did not have 
private health insurance. 
Table 4.19 Demographic characteristics of urban and rural participants. 
Characteristic urban% rural p value 
n(%) n(%) 
Age (n = 170) 
< 65 30 (38.5) 36 (39.1) 0.929 
> 65 48 (61.5) 56 (60.9) 
Marital Status (n = 165) 
Un-partnered 8 (10.7) 12 (13.3) 0.601 
Partnered 67 (89.3) 78 (86.7) 
Dependents (n = 164) 
Yes 17 (22.7) 15 (16.9) 0.349 
No 58 (77.3) 74 (83.1) 
Employment Status (n = 169) 
Full-Time/self-employed 11 (14.1) 7 (7.7) 
Part-Time/semi-retired 6 (7.7) 8 (8.8) 
Seasonal/sick 5 (6.4) 9 (9.9) 0.510 
leave/unemployed/other 
Retired 56 (71.8) 67 (73.6) 
Education (n = 166) 
Less than high school 11 (14.7) 45 (49.5) 
Completed high school 17 (22.7) 17 (18.7) 0.000* 
Some post secondary 12 (16.0) 12 (13.2) 
Completed post secondary 19 (25.3) 11 (12.1) 
Graduate/professional degree 16 (21.3) 6 (6.6) 
Income (n = 170) 
< $19,999 3 (3.8) 21 (22.8) 
$20,000 - $29,999 11 (14.1) 27 (29.3) 
$30,000 - $39,999 18 (23.1) 15 (16.3) 
$40,000 - $49,999 12 (15.4) 13 (14.1) 0.000* 
$50,000- $59,999 12 (15.4) 7 (7.6) 
$60,000 - $69,999 5 (6.4) 5 (6.4) 
> $70,000 17 (21.8) 4 (4.3) 
Have Private Insurance (n = 161) 
Yes 39 (80.8) 45 (51.1) 0.000* 
No 14 (19.2) 43 (48.9) 
Know about MTAP (n = 139) 
Yes 28 (49.1) 28 (34.1) 0.077 
No 29 (50.9) 54 (65.9) 
* statistically significant; p<O.OS 
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Compared to urban residents, a larger proportion of rural residents had been 
diagnosed either 7-12 or 13-24 months earlier (Table 4.20). There are no other 
differences in the clinical characteristics between the two groups. 
Table 4.20 Clinical characteristics of urban and rural participants. 
Clinical Characteristics urban°/o rural 
n(%) n(%) p value 
Time Since Diagnosis (n = 167) 
0-6 months 17 (22.1) 15 (16.7) 
7-12 months 25 (32.5) 33 (36.7) 0.016* 
13 - 24 months 11 (14.3) 28 (31.1) 
24 months+ 24 (31.2) 14(15.6) 
Current Treatment (n = 170) 
Radiation 
Yes 8 (10.3) 11 (12.0) 0.726 
No 70 (89.7) 81 (88.0) 
Hormone Therapy 
Yes 15(19.2) 13 (14.1) 0.372 
No 63 (80.8) 79 (85.9) 
Chemotherapy 
Yes 0 (0.0) 0 (0.0) .a 
No 78 (100.0) 92(100.0) 
Active Treatment 
Yes 26 (33.3) 36 (39.1) 0.434 
No 52 (66.7) 56 (60.9) 
Other 
Yes 5 (6.4) 11 (12.0) 0.217 
No 73 (93.6) 81 (88.0) 
Active Treatment or Follow-up 
Yes 21 (26.9) 25 (27.2) 0.971 
No 57 (73.1) 67 (72.8) 
Past treatment (n = 169) 
Radiation 
Yes 24 (30.8) 27 (29.7) 0.877 
No 54 (69.2) 64 (70.3) 
Hormone Therapy 
Yes 10 (12.8) 12 (13.0) 0.966 
No 68 (87.2) 80 (87.0) 
Chemotherapy 
Yes 0 (0.0) 1 (1.1) 0.356 
No 78 (100.0) 91 (98.9) 
Surgery 
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Yes 44 (56.4) 41 (44.6) 0.124 
No 34 (43.6) 51 (55.4) 
Prostatectomy 
Yes 39 (50.0) 36(39.1) 0.155 
No 39 (50.0) 56 (60.9) 
TURP 
Yes 3 (3.8) 0 (0.0) 0.058 
No 75 (96.2) 92(1 00.0) 
Orchiectomy 
Yes 0 (0.0) 2 (2.2) 0.190 
No 78 (100.0) 90 (97.8) 
Other 
Yes 1 (1.3) 0 (0.0) 0.276 
No 77 (98.7) 92(100.0) 
Length of Time Receiving Treatment 
(n = 75) 
< 3 months 11 (36.7) 20 (44.4) 
3-6 months 5 (16.7) 7 (15.6) 0.793 
6 months - 1 year 14 (46.7) 18 (40.0) 
Drugs taken (n = 170) 
Hormone Treatment 
Yes 13 (16.7) 20 (21.7) 0.405 
No 65 (83.3) 72 (78.3) 
Supportive 
Yes 9 (11.5) 10 (10.9) 0.890 
No 69 (88.5) 82 (89.1) 
Vitamins/Supplements 
Yes 7 (9.0) 6 (6.5) 0.549 
No 71 (91.0) 86 (93.5) 
Miscellaneous 
Yes 5 (6.4) 2 (2.2) 0.166 
No 73 (93.6} 90 (97.8) 
* statistically significant; p<0.05 
Table 4.21 compares the OOP costs (dollar value) of urban and rural patients. 
Although there was no difference in the costs for drugs and supplies or total, a larger 
proportion of rural residents than urban residents reported costs up to $500 and 
greater than $500 in the previous quarter for travel. 
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Table 4.21 Three month Out-of-pocket costs, All Costs category, for urban and rural 
rf · t pa ICipan s. 
Cost urban% rural 
n(%) n(%) p_ value 
Drugs and Supplies 3 Month(n = 170) 
$0 59 (75.6) 62 (67.4) 0.074 
$0.01 - $499.99 15 (19.2) 29 (31.5) 
>$500.00 4 (5.1) 1 (1.1) 
Travel 3 month (n = 170) 
$0 61 (78.2) 47 (51.1) 0.001 * 
$0.01 - $499.99 11 (14.1) 27 (29.3) 
>$500.00 6 (7.7) 18 (19.6) 
All Costs 3 Month (n = 170) 
$0 49 (62.8) 42 (45.7) 0.077 
$0.01 - $499.99 18 (23.1) 29 (31.5) 
>$500.00 1 1(14.1) 21 (22.8) 
* Statistically significant; p<0.05 
Table 4.22 compares the proportion of income consumed by OOP costs of 
urban and rural patients for a three month period. Although there was no difference 
in the costs for drugs and supplies or total, a larger proportion of rural residents than 
urban residents reported costs up to 7.49% and greater than 7.5% in the previous 
quarter for travel. 
Table 4.22 Percent of income consumed for urban rural participants. 
%of Quarterly Income urban% rural 
Consumed n(%) n(%) p value 
Drugs and Supplies (n = 170) 
0% 59 (75.6) 62 (67.4) 
0.01 -7.49% 16 (20.5) 29 (31.5) 0.157 
7.50+% 3 (3.8) 1 (1.1) 
Travel (n = 169) 
0% 61 (79.2) 47 (51.1) 
0.01 -7.49% 11 (14.3) 31 (33.7) 0.001 * 
7.50+% 5 (6.5) 14 (15.2) 
All costs (n = 170) 
0% 49 (62.8) 42 (45.7) 
0.01 -7.49% 20 (25.6) 32 (34.8) 0.075 
7.50+% 9 (11.5) 18(19.6) 
* Statistically significant; p<0.05 
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As shown in Table 4.23 there was no difference in the proportion of urban and 
rural residents who reported using either drug or appointment related coping 
strategies. 
Table 4.23 Use of coping strategies for urban and rural participants. 
Coping strategies urban% rural 
n(%) n(%) p value 
Drug Coping Strategies (n = 170) 
Yes 4(5.1) 10(10.9) 0.175 
No 74 (94.9) 82 (89.1) 
Appointment Coping Strategies (n = 170) 
Yes 3 (3.8) 3 (3.3) 0.837 
No 75 (96.2) 89 (96.7) 
* Statistically significant; p<0.05 
There was also no difference in the quality of life scores reported by urban 
and rural residents (Table 4.24). 
Table 4.24 Quality oflife for urban and rural participants. 
Quality of Life urban% rural 
mean (sd) mean (sd) p value 
FACTG Total (n = 126) 86.02 (13.686) 84.1 0(14.228) 0.445 
FACT P Total (n=126) 117.81(17.811) 116.64(20.086) 0.733 
* Statistically significant; p<0.05 
Compared to urban residents a larger proportion of rural residents reported 
that cancer care costs created a lot of stress and that cancer costs were more stressful 
than other things (Table 4.25). There were no other significant differences in the 
attitudes and beliefs of urban and rural residents. 
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Table 4.25 Attitudes regarding OOP costs for urban and rural participants. 
Attitudes urban% rural 
n(%) n (%) p value 
OOP costs influenced treatment 
decisions 
Agree 4 (7.1) 5 (7.2) 0.982 
Disagree 52 (92.9) 64 (92.8) 
Doctor aware of my OOP costs 
Agree 14 (26.4) 17 (27.4) 0.904 
Disagree 39 (73.6) 45 (72.6) 
Doctor takes costs into account 
Agree 6 (11.5) 9 (14.5) 0.639 
Disagree 46 (88.5) 53 (85.5) 
Cancer costs create a lot of stress 
Agree 10 (18.2) 23 (34.8) 0.040* 
Disagree 45 (81.8) 43 (65.2) 
Cancer costs more stressful than other 
things 
Agree 7 (12.7) 19 (28.4) 0.036* 
Disagree 48 (87.3) 48 (71.6) 
Trouble paying for my cancer costs 
Agree 4 (7.3) 11 (16.9) 0.111 
Disagree 51 (92.7) 54 (83.1) 
Aware of assistance programs 
Agree 14 (25.5) 19 (28.8) 0.682 
Disagree 41 (74.5) 47 (71.2) 
Prescription drugs free to everyone 
Agree 36 (64.3) 42 (59.2) 0.555 
Disagree 20 (35.7) 29 (40.8) 
Prescription drugs free to low income 
people 
Agree 49 (83.5) 61 (84.7) 0.795 
Disagree 10 (16.9) 11 (15.3) 
Assistance programs well advertised 
Agree 10 (16.4) 7 (9.9) 0.264 
Disagree 51 (83.6) 11 (15.3) 
* Statistically significant; p<0.05 
70 
Chapter 5: Discussion 
5.1. Study 
Using a self-administered, written survey of a sample of men diagnosed with 
prostate cancer, we described the OOP costs associated with prostate cancer care in 
Newfoundland and Labrador. We also examined the association between costs and 
cost saving strategies and attitudes. Finally, we compared the costs, use of cost 
saving strategies and the attitudes of men who lived in urban and rural communities. 
5.2. Costs 
We assessed costs over two time periods and using two measures. We 
examined costs incurred during the previous one month and during the previous three 
months (quarter). While recall is better over the shorter period, costs incurred may be 
highly variable. For example, if prescriptions are filled for six weeks or three 
months, capturing only the expenses accrued in the previous one month may be 
inaccurate if the value is too low (if the prescription was not filled) or too high (if the 
prescription was filled). Although assessing costs over a three month period may 
provide more stable values, participants may have poorer recall of expenses. By 
considering costs over the two periods, we were able to address these potential threats 
to validity. 
Costs were measured as actual dollar amounts as well as the proportion of 
income consumed by these costs. It is important to understand these two variations of 
costs as an actual dollar amount may hold different consequences for individuals. 
One thousand dollars of OOP cancer related costs might substantially affect someone 
with a low income but have less impact on someone with higher income. While it is 
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Important to understand actual dollar amounts of OOP cancer related costs, 
determmmg the proportiOn of mcome that IS consumed by OOP cancer related costs 
provides a better mdicator of the financial burden of cancer to mdiVIduals (Moore, 
1998) Also, measunng OOP costs as a proportion of mcome allows us to exam me 
costs m relation to means-tested assistance programs such as the public drug plans 
offered m Newfoundland and Labrador (Government of Newfoundland and Labrador, 
n d ) It also facilitates compansons between provmces and countnes, and at different 
pomts m time 
Although the maJonty of men with prostate cancer reported no OOP costs m 
the prevwus month or previOus quarter, a small proportion of men patd m excess of 
$500 for OOP cancer costs m the last month (14 1 %) or previOus quarter (18 8%) 
When considered m terms of proportiOn of mcome, 21 2% spent more than 7 5% of 
their mcome on OOP costs m the previous month (15 9% spent more than 7 5% of 
their mcome on OOP costs m the prevwus quarter) These findmgs are consistent 
with previOus studies of OOP costs for cancer patients m NL (Mathews and Basky, 
2004) and Ontano (Longo et al, 2006, Longo et al, 2007) Mathews and Basky 
(2004) found that 19 8% of cancer patients spent more than $1000 for theu last tnp 
for cancer care6 
There was no relationship between time smce diagnosis and amount of costs 
This findmg may be umque to prostate cancer, unhke other cancer diagnoses, there 
may be httle active treatment Immediately followmg discovery OOP costs appear to 
accrue once treatment other than surveillance (or watchful wattmg) begms Further 
6 The study exammes costs for a smgle tnp away from the men's home commumty One tnp could 
entail multiple VISits at the cancer chmc 
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study of the OOP costs associated with other types of cancer is needed to test this 
hypothesis. 
5.2.1 Drug Costs 
Only a very small proportion of men reported high drug costs (in excess of 
$500 or 7.5% of income) in either the previous month or previous quarter. Although 
other Canadian studies have reported higher drug costs among cancer patients, these 
included breast, lung, colorectal and prostate cancer patient together (without 
providing cancer specific estimates) (Longo et al., 2006; Longo et al., 2007; Mathews 
and Basky, 2004). Despite reporting higher cancer related drug costs, these studies 
also found that costs were very high for a small group of patients. 
The small proportion of men reporting any drug costs may be explained by the 
small numbers of men who reported taking any drugs for the prostate cancer; 
relatively few men reported that they were taking hormone treatment (19.4%), 
supportive drugs (11.2%) vitamins and/or supplements (7.6%) or other prostate 
cancer related drugs ( 4.1% ). We found that a larger proportion of men taking 
hormone treatment, supportive drugs (such as Demerol, viagara, ibuprofen, 
hydrocortisone, and oxycodone) or vitamins/supplements such as Vitamins B 12, C, 
D, calcium, lycopene and glucosamine) reported higher costs over a three month 
period (whether considered in actual dollars or proportion of income consumed by 
OOP cancer costs). While hormone therapy and supportive drugs are prescribed by a 
physician, with the exception of vitamin D7, there is little conclusive evidence to 
support taking vitamins and supplements for prostate cancer. Studies have suggested 
7 Men with prostate cancer are encouraged to consult their physician about taking one thousand 
international units (IU) daily during the fall and winter seasons (CCS, 2009b). 
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that use of supplements such as antioxidants may not only be potentially ineffective 
but may also be harmful when used in combination with chemotherapy or radiation 
therapy (D'Andrea, G. M., 2005; Lawenda et al., 2008). Moreover, the Canadian 
Cancer Society notes that eating a healthy diet is the best way of getting daily 
requirements of vitamins and supplements (Canadian Cancer Society, 2009c). Given 
that vitamins and supplements can account for substantial OOP costs, our findings 
suggest that there is a need to educate men about the potential benefits and drawbacks 
of taking vitamins and supplements. 
Low OOP drug costs may also be due to formal and informal financial 
subsidies that men may be receiving. Formal programs include public and private 
insurance programs. Almost two-thirds (64.6%) of the men in our sample had private 
health insurance. In addition, men may have started to receive subsidies through the 
Assurance Plan which was added to the Newfoundland and Labrador Drug Plan, in 
2007 (Government of Newfoundland and Labrador, n.d). The Assurance Plan 
subsidizes drug costs above income related thresholds (see Section 2.2.2.1). Men 
may also benefit from "compassionate release", an informal program offered in the 
cancer clinic (Mathews et al, 2009c). In these programs, drug companies may 
provide drug costs at reduced or no costs to patients in need. In Newfoundland and 
Labrador, the program is informally run with requests made by health care providers 
in the cancer clinic. The program provides approximately $1.5 million worth of 
drugs to patients (all cancer types) each year. There are no exclusion criteria; 
however, staff assigned to the program determine whether other support programs or 
coverage is available before referring patients to the compassionate care programs (J. 
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Greenland, personal communication, November 21, 2009 ). In other parts of Canada, 
the majority of compassionate release are means tested (based on income)and are 
available to those who are without private insurance (BC Cancer Agency, 2009). 
Some programs will assist patients in finding third party insurance or have a co-pay 
system. 
5.2.2 Travel Costs 
A larger proportion of men in the study reported high travel related OOP 
costs, 14.1% had costs in excess of $500 and 11.2 had costs in excess of 7.5% of their 
income). For men in our study, travel costs were largely responsible for the total 
amount of costs, accounting for 85% of all costs among men who had any costs in the 
previous quarter or 63% of costs in the previous month. Not surprisingly, a larger 
proportion of rural residents reported higher travel costs. These findings are also 
consistent with previous studies NL (Mathews and Basky, 2004). High travel costs 
are due to the centralization of specialists (urologists and oncologists) in the larger 
centres in the province and availability of radiation therapy, one of the main forms of 
treatment for prostate cancer (Carroll et al., 2005), in St. John's. Patients who live 
outside of St. John's and who require radiation treatment incur substantial costs in 
travel and lodging for radiation treatment which can last weeks at a time. Likewise, 
men who are treated with "watchful waiting" may need to travel to a larger centre to 
see their urologist. Although our study limited travel costs to those incurred in the 
previous month and previous quarter, many respondents noted in survey that they had 
high travel costs (in excess of$1,000) when they had to access treatment in St. John's 
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or outside the province, even though it had not been incurred in the previous one or 
three months. 
5.3. Cost Saving Strategies 
Very few men in the study reported using any cost saving strategies; only 
8.2% reported ever using a drug related coping strategy and only 3.5% reported ever 
using an appointment related strategy. The slightly higher rate of drug versus 
appointment related strategies may be due to drug-related strategies being "less 
conspicuous" to health care providers since they would be less likely to know or to 
notice a missed pill than a missed appointment. Moreover, patients may believe that 
some treatment (e.g. rationing or substituting drugs is better than no treatment 
(missing an appointment). Studies in the US have reported higher rates of cost saving 
strategies (Piette, Heisler, & Wagner, 2004; Federman, 2004). For example, Piette et 
al. found that overall 18% of patients surveyed reported using some form of drug 
coping strategy or "underuse" of medication at least once in the previous year. In 
addition they also found that 14% of all respondents underused medication at least 
once a month during the previous year. However, these studies included patients with 
other chronic conditions such as diabetes and hypertension. We hypothesize that 
patients may be less willing to compromise cancer related care than care for other 
chronic conditions. Further research is needed to test this hypothesis. 
There was some association between costs and use of any cost saving strategy. 
Compared to men with no costs, a larger proportion of men with high costs used drug 
related coping strategies ($500 or more or 7.5% or more of income) and appointment 
related strategies (7 .5% or more of income). Significant results were seen in relation 
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to costs over three month period but not one month. The low rate of drug or 
appointment related strategies, suggests that although costs may be high for some 
patients, it does not generally result in patient driven changes to care. Although a 
previous qualitative study suggested that patients use drug and cost related strategies 
to curb OOP cancer costs (Mathews et al., 2009b ), our study suggests that the use of 
these strategies is generally rare among prostate cancer patients. 
There was also no significant difference in the use of cost saving strategies of 
urban and rural residents. A previous study ofbreast, lung, colorectal and prostate 
cancer patients found rural residents were more likely than urban residents to consider 
drug and travel related OOP costs as important in the cancer care decisions (Mathews 
et al., 2009a). However, we did not find differences in the current and previous 
treatments reported by urban and rural residents in our study. Moreover, few 
respondents agreed when asked whether OOP costs influenced their treatment 
decisions for their prostate cancer. There was also no significant difference in the 
quality of life scores of men with high and low costs. These findings suggest that 
while costs may be important considerations, they generally affect the treatment 
decisions of a very small proportion of prostate cancer patients, if at all. 
There is also a strong culture and willingness in Newfoundland and Labrador 
to help those in need. Anecdotally, patients or friends and family of those going 
through cancer, particularly in rural communities, may find their community rallying 
around them by raising funds to cover the costs of their cancer care (Mathews & 
Basky, 2003). This may explain why few men use coping strategies despite one in 
nine men reporting OOP costs of more than 7.5% of their income. 
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5.4 Cost Related Stress and Quality oflife 
Roughly one quarter (27.3%) of the men surveyed reported that OOP costs 
created stress, 21.3% said those costs created more stress than other things in their 
life. Although higher costs in the previous month was associated with stress, we did 
not find a similar association when considering costs over a three month period. This 
may be due to the way in which costs are incurred, that is, a trip or a prescription may 
be required every quarter rather than every month. Men who just travelled or filled a 
prescription may have accumulated a substantial number of expenses (and had a 
substantial outlay of money) causing a "cash flow" problem. Or, some assistance 
programs may require men to pay costs "up-front" and then submit claims for 
subsidies at a later time. 
A larger proportion of rural residents than urban residents agreed that OOP 
cost caused more stress than other sources of stress in their lives. This finding is 
consistent with other results in the study and previous studies of rural cancer patients 
that showed that rural residents have greater out-of pocket costs that can amount to 
thousands of dollars for a single trip away from home (Lauzier et al., 2005; Mathews 
and Basky, 2004; Mathews et al., 2009a). Lauzier and colleagues, (2005), found that 
cancer patients from rural areas found OOP costs to be worrisome if they did not have 
sufficient means to pay for these costs. These financial concerns, added to the stress 
and worry of the cancer itself. 
5.5 Awareness and support of assistance programs 
Less than one third of patients (27.0%) discussed cancer related OOP costs 
with their physicians and less than one in seven (13.2%) agreed that their doctor takes 
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costs into account when prescribing drugs for them. In addition, there was no 
consistent relationship between the amount of OOP costs incurred and discussing 
costs with physicians or physicians who took costs into account when prescribing 
drugs. These findings concur with other studies in the US. For example, US 
researchers report that only 15-16% of patients discussed OOP drug related costs with 
their physicians (Alexander, Casalino, & Meltzer, 2003; Piette, Heisler, & Wagner, 
2004) and that only one third of physicians discussed drug costs with their patients 
(Alexander, Casalino, & Meltzer, 2003). Piette and colleagues (2004) listed several 
reasons why patients did not discuss costs with their physicians: they had not been 
asked (66%), they did not think their health care providers could help (58%), they 
were too embarrassed (45%), they did not think the issue was important (45%), there 
was insufficient time during the visit (31 %), there was a lack of trust (11 %). In a 
qualitative study, Mathews and Park (2009) highlighted a number ofbarriers to 
identifying patients with financial concerns in Newfoundland and Labrador. These 
barriers included a lack of a standardized assessment tool, a lack of ongoing 
screening, and patients' lack of knowledge of financial concerns as well as their 
unwillingness to disclose these concerns. 
It is possible that patients may have discussed financial concerns with other 
members of the cancer care team besides physicians. Increasingly as cancer care is 
provided in interdisciplinary teams, health care providers such as social workers or 
nurses may be tasked with assessing financial risks. Future studies should also 
examine the role of the team in assessing financial risk. 
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The 'danger' of health care providers not knowing about patients financial 
concerns is that the providers may not refer patients to assistance programs (Wagner 
& Lacey, 2004). In fact, only 27.3% of men in our study were aware of financial 
assistance programs and only 12.9% believed these programs were well advertised. 
These findings are in line with previous studies (Mathews and Park, 2009; Mathews 
et al., 2006; Wagner and Lacey, 2004) and highlight the need to educate patients 
about resources that are available to them in the province in order to reduce the 
burden of OOP cancer related costs. For example, a number of respondents could 
potentially qualify for one of the four plans that make up the NL Public Drug Plan 
because of their age ( 61.2% were over 65 years old) or the proportion of the their 
income consumed by OOP cancer costs (Government ofNewfoundland and 
Labrador, n.d.). There was strong support for public "pharmacare" plans, especially 
for low income families, among the men in our study, regardless of the OOP costs 
incurred. 
5.6. Limitations 
There are a number of limitations to this study. First we had to use a variety 
of methods to conduct surveys with eligible participants. We had originally planned 
to recruit patients from the Cancer Clinics and support groups in the province. 
Although there was a high level of assistance and participation from support groups, 
we were unable to recruit many new patients, or patients who did not belong to a 
support group. 
For this study, the Human Investigations Committee did not permit 
researchers to make the first contact with patients. As a result, we were dependent on 
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the cancer clinic staff to tell patients about the study and refer patients to the 
researcher. However, there was a substantial level of reluctance among staff to 
recruit patients for the survey or have a researcher available in the cancer clinic 
waiting rooms. As a result, we had to modify recruitment to passive means, such as 
using posters. These methods took a substantial amount oftime and did not result in 
many respondents, particularly in the St. John's clinic. Ultimately we resorted to a 
mailed survey despite the limitations of a mailed survey to collect complete and 
sensitive data (Aday, 1996). These experiences highlight the need for improved 
support from the cancer clinics for research projects and facilitating access to cancer 
patients for researchers. Although we used different methods used to recruit our 
sample, we obtained a representative sample of respondents in terms of urban/rural 
residence and age. 
We used the Cancer Registry to generate a list of recently diagnosed prostate 
cancer patients for the mailed survey. Because we decided to use a mail survey when 
other methods did not work, we did not have a large budget to fund it. Although we 
had a reasonable response rate given limited resources, future studies using the 
registry for surveys should allow for multiple mail-outs and reminders (Dillman, 
2007). Using the Registry to create the sample frame requires that it be complete, 
valid, reliable and timely (Menck, Denpen, Phillips, and Tucker, 2007). Although 
efforts are underway to improve the cancer registry in the province, there are a 
number of problems with the Cancer Registry in NL. The North American 
Association of Central Cancer Registries, which assess the completeness and quality 
of registries, has never certified the Newfoundland and Labrador cancer registry 
81 
(North American Association of Central Cancer Registries, 2007). Moreover the 
Canadian Cancer Statistics noted problems with the quality of the data on the NL 
registry (CCS/National Cancer Institute of Canada, 2008). Despite these limitations 
with the registry, it was the only way to identify prostate cancer patients in the 
province. 
Although we asked stage at diagnosis in the survey, we did not report these 
findings because of the poor quality of the data. Many respondents did not answer 
this question. Moreover, many responded with qualitative answers (e.g. "early", 
"good", etc.) rather than Gleason scores. Subsequent discussions with prostate cancer 
patients suggested that not all physicians inform patients of the stage of the prostate 
cancer to the patient. 
The sample size was smaller than originally anticipated (due in part to the 
difficulties with recruitment). However, the sample was large enough to detect a 
difference as small as 3.9 points between urban and rural participants (with a two tail 
test, power of0.8 and an alpha of0.05). The sample size calculation was based on the 
FACT-P instrument, which has a mean of67 and standard deviation of8.7 (Esper et 
al., I 997). 
However, given the very small number of respondents with high costs, we 
may not have sufficient power to detect significant differences in our comparisons of 
men with different amounts of costs. Moreover, we did multiple comparisons, 
thereby increasing the likelihood that some of the differences we found were due to 
chance. 
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Chapter 6: Conclusions and Recommendations 
This study described the types and amounts of OOP costs incurred by prostate 
cancer patients in Newfoundland and Labrador and examined whether OOP costs of 
prostate cancer have any affect on patients' attitudes, use of cost management 
strategies and quality of life. It also looked at differences in the costs, attitudes, use 
of cost management strategies and quality oflife of urban and rural residents. This 
study increases our understanding of how cancer patients and their families manage 
the financial burden associated with cancer care. It provides health care providers, 
system administrators and patient advocates with evidence with which to improve the 
accessibility of cancer care in the province. 
We found that although most men with prostate cancer incur no, or very little 
OOP care related costs, a small but substantial proportion of men with prostate cancer 
had significant costs. Almost 1 in 5 men (18.8%) paid more than $500 in the last 
quarter. For roughly 1 in 6, these OOP costs accounted for more than 7.5% of their 
quarterly income. While higher OOP costs were related to greater stress, there were 
few other differences between men with high and low OOP costs. Very few men 
reported that they compromised their care, by using drug or appointment related 
strategies to reduce their OOP costs. We also did not find significant differences in 
the quality of life or care received by men with different levels of costs. High OOP 
costs were generally related to the costs of travel and lodging. Therefore, it was not 
surprising that rural men generally reported higher OOP costs than urban men. Aside 
from higher stress related to OOP costs, there were few other differences in the use of 
cost saving strategies, quality of life or attitudes of urban and rural men. 
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These findings suggest that although OOP costs for prostate cancer care are high 
for a small group of men, OOP costs rarely affect care. This may suggest that 
Canadian public health insurance, as well as formal and informal drug (e.g. 
compassionate leave) programs are working to remove financial barriers to care. 
Nonetheless, costs related to travel and lodging remain a substantial financial barrier 
for patients from rural communities. While the provincial government reimburses 
individuals for some costs relating to travel for health services through the Medical 
Travel Assistance Program, some costs remain ineligible, such as mileage for a 
private vehicle. Expanding the eligibility criteria for the programs may reduce the 
financial burden faced by prostate cancer patients, particularly those in rural areas. 
However, further research is needed to assess the OOP costs and their consequences 
among patients with other types of cancer as well as with prostate cancer patients in 
other provinces. 
Despite the concerns regarding OOP costs, relatively few men tell their 
physicians about their OOP costs or believe that their doctor takes costs into account 
when prescribing drugs. We also found that most men in our study were unaware of 
financial assistance programs or felt that they were well advertised. These findings 
suggest there is a need to educate patients about subsidy programs and promote 
discussions between patients and health care providers about OOP cancer related 
costs. 
Lastly, we experienced considerable difficulty accessing patients through the 
cancer clinic. There is a need to improve support for research within the cancer care 
program. Their support is integral to future applied health research involving cancer. 
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Prostate Cancer Patients' Out-of-Pocket Costs 
First, we would like to find out more about your cancer diagnosis. 
1 . When were you first diagnosed with prostate cancer? 
_____ (month) _____ (year) 
2. What was your stage of cancer when diagnosed? ________ _ 
3. Is this your first cancer diagnosis? 
D Yes 
D No 
4. Are you currently being treated for any other type of cancer? 
D Yes 
D No 
5. What treatment are you currently receiving for your prostate cancer? 
(check all that apply) 
D Radiation 
0 Hormonal therapy (eg. LHRH agonists, antiandrogens) 
D Chemotherapy (eg. Docetaxel (Taxotere)) 
D No active treatment; regular follow-up 
D Other: 
----------------
6. What treatment have you previously had for your prostate cancer? (check 
all that apply) 
0 Radiation 
D Hormonal therapy (eg. LHRH agonists, antiandrogens) 
D Chemotherapy (eg. Docetaxel (Taxotere)) 
D Surgery, if so, which kind 
o Prostatectomy (removal of prostate) 
o TURP (enlargement of urethra) 
o Orchiectomy (removal of testes) 
o Other: please specify ________ _ 
D Other: ____________ _ 
7. How long have you been receiving treatment? 
D Less than 3 months 
D 3-6 months 
0 Between six months and a year 
8. Are you taking part in any clinical trials for cancer treatment? 
D Yes 
D No 
The next section will ask about the out-of-pocket costs for your prostate cancer 
care. We are interested in those costs that were not covered by insurance or 
assistance programs. 
9. Thinking about the last month, please indicate how much you spent for 
each of the following in the first column? Next, thinking about the last 
three months, please indicate how much you spent for each of the 
following in the second column? 
Type of cost 
Amount 
per month 
Amount($) 
last 3 months 
Prescription drugs for prostate cancer 
Over the counter drugs for prostate cancer 
Natural or alternative medications (such as herbal 
medications 
Transportation for cancer care 
Gas and/or Rental Car 
Bus/taxi 
Plane tickets 
Other (please list _____ _J 
Lodging while receiving cancer care 
Hotel 
Motel 
Hostel 
Other (please list _____ .J 
Meals while at the cancer clinic 
Costs for companion/escort 
Communication while at the cancer clinic (phone, internet, 
mail 
Parking (at the cancer clinic) 
Supplies (such as bandages etc) 
Care for a child/ or elder 
Lost wages 
Other (please list ______ _ 
2 
10. How did costs for this month compare to other months since you have 
been diagnosed with prostate cancer? 
0 More than other months 
0 Similar to other months 
0 Less than other months 
11 . How did/do you pay for these costs? (check all that apply) 
0 Savings 
0 Help or loan from family/friends 
0 Sold belongings 
0 Fundraiser 
0 Bank loan 
0 Social Assistance/Income support 
0 Veteran's benefits 
0 Medical Transportation Assistance program 
0 Other assistance program from cancer clinic or hospital 
0 Other: please describe _________ _ 
12. What drugs are you taking in relation to your cancer treatment? (List all 
that apply) 
13. Are these drugs covered by your insurance? 
0 Yes 
0 No 
14. Do you know about the Medical Transportation Assistance Program 
(MT AP) offered by the Provincial Government? 
0 Yes 
If yes, have you or do you planning to apply to it for assistance? 
o Yes 
o No 
0 No 
3 
In the next question, we would like to know how you are managing these costs. 
15. On a scale from 1 to 5, where 1 is "never" and 5 is "all of the time", since you were diagnosed with 
prostate cancer, how often do you do the following: (please circle one number for each point) 
Never Not Some Most of All of 
very of the the time the time 
often time 
a. Spread out a medication over a longer period of 1 2 3 4 5 
time to make it last longer 
b. Replaced the medication your doctor prescribed 1 2 3 4 5 
with another cheaper one 
c. Skipped one or more dose of medication to save on 1 2 3 4 5 
costs 
d. Bought only what you thought was the most 1 2 3 4 5 
important medication 
e. Not filled a prescription because of the cost 1 2 3 4 5 
f. Delayed fililng a prescription because of the cost 1 2 3 4 5 
g. Asked my doctor for free samples of a drug 1 2 3 4 5 
h. Spread out the time between visit to the doctor for 1 2 3 4 5 
follow-up visit 
i. Missed or cancelled an appointment with the cancer 1 2 3 4 5 
clinic to save money 
j. Missed or cancelled scheduled cancer treatment to 1 2 3 4 5 
save money 
16. On a scale from 1 to 5, where 1 is strongly disagree" and 5 is "strongly agree", how much do you 
agree or disagree with the following statement: (please circle one number for each point) 
Strongly Neither 
Disagree Disagree Agree or Agree Strongly 
Disagree Agree 
a. My out-of-pocket costs influenced my decisions 1 2 3 4 5 
about how to treat my prostate cancer 
b. My cancer doctor is aware of my out-of pocket 1 2 3 4 5 
costs for my prostate cancer 
c. My doctor takes costs into account when 1 2 3 4 5 
prescribing drugs for me 
d. My cancer related costs create a lot of stress 1 2 3 4 5 
e. Cancer costs create more stress for me than 1 2 3 4 5 
other sources of stress in my life 
f. I am having trouble paying for my cancer costs 1 2 3 4 5 
g. I am aware of assistance programs to help me 1 2 3 4 5 
with cancer costs 
h. All prescription drugs should be free to 1 2 3 4 5 
everyone, regardless of their income 
i. All prescription drugs should be free to people 1 2 3 4 5 
with low income 
j. Assistance programs are well advertised. 1 2 3 4 5 
4 
17. Below is a list of statements that other people with your illness have said are important. By circling 
one (1) number per line, please indicate how true each statement has been for you during the past 
7days. 
Not at A little Some- Quite a Very 
Physical well-being all bit what bit much 
a. I have a lack of energy 1 2 3 4 5 
b. I have nausea 1 2 3 4 5 
c. Because of my physical condition, I have 1 2 3 4 5 
trouble meeting the needs of my family 
d. I have pain 1 2 3 4 5 
e. I am bothered by side effects of treatment 1 2 3 4 5 
f. I feel ill 1 2 3 4 5 
g. I am forced to spend time in bed 1 2 3 4 5 
Social/Family well-being 
a. I feel close to my friends 1 2 3 4 5 
b. I get emotional support from my family 1 2 3 4 5 
c. I get support from my friends 1 2 3 4 5 
d. My family has accepted my illness 1 2 3 4 5 
e. I am satisfied with family communication 1 2 3 4 5 
about my illness 
f. I feel my friends and acquaintances avoid 1 2 3 4 5 
me. 
g. I feel close to my partner (or the person 1 2 3 4 5 
who is my main support) 
Regardless of your current level of sexual activity, please answer the following question. If you 
prefer not to answer it, please check this box D and go to the next section. 
h. I am satisfied with my sex life 1 2 3 4 5 
Emotional Well-being 
a. I feel sad 1 2 3 4 5 
b. I am satisfied with how I am coping with 1 2 3 4 5 
my illness 
c. I am losing hope in the fight against my 1 2 3 4 5 
illness 
d. I feel nervous 1 2 3 4 5 
e. I worry about dying 1 2 3 4 5 
f. I worry that my condition will get worse 1 2 3 4 5 
Functional Well-being 
a. I am able to work (include work at home) 1 2 3 4 5 
b. My work (include work at home) is fulfilling 1 2 3 4 5 
c. I am able to enjoy life 1 2 3 4 5 
d. I have accepted my illness 1 2 3 4 5 
e. I am sleeping well 1 2 3 4 5 
f. I am enjoying the things I usually do for fun 1 2 3 4 5 
5 
Not at A little Some- Quite a 
Additional Concerns all bit what bit 
a. I am losing weight 1 2 3 4 
b. I have a good appetite 1 2 3 4 
c. I have aches and pains that bother me 1 2 3 4 
d. I have certain parts of my body where I 1 2 3 4 
experience significant pain 
e. My pain keeps me from doing things I want to 1 2 3 4 
do 
f. I am satisfied with my present comfort level 1 2 3 4 
g. I am able to feel like a man 1 2 3 4 
h. I have trouble moving my bowels 1 2 3 4 
i. I have difficulty urinating 1 2 3 4 
j. I urinate more frequently than usual 1 2 3 4 
k. My problems with urinating limit my activities 1 2 3 4 
I. I am able to have and maintain an erection 1 2 3 4 
Finally, the following questions will ask a little bit about yourself and will be 
helpful in describing who is affected by out-of-pocket costs of cancer, and how. 
18. In what year were you born? 
19.1n which town/city do you live? 
20. What is your postal code? 
21. Which best describes your current situation? (Please choose one 
response only) 
D Full-time job 
D Part-time job 
D Self-employed 
D Seasonai/EI 
D Sick leave (paid) I Long term disability 
D Strike 
D Unemployed 
D Semi-retired 
D Retired 
D Caring for someone full-time 
D Homemaker 
D Student 
D Other ____________ __ 
6 
Very 
much 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
22. As a result of your cancer diagnosis, did your work situation change? 
(check all that apply) 
0 Yes. 
If yes, how? 
o Working less 
o Working more 
o Went back to work 
o Had to quit during treatment 
o Went on leave during treatment 
o Other - please describe: ________ _ 
0 No 
23. What is your highest level of education? 
0 Did not complete high school 
0 Completed high school 
0 Did some community college, technical school, or university 
0 Completed community college, technical school, or university 
0 Completed post-graduate or professional training 
24. What is your marital status? 
0 Married/living with partner 
0 Single - divorced/separated 
0 Single- never married 
0 Single -Widower 
25. Do you have any children or elderly relatives to care for? 
0 Yes 
o Children 
• How many? ____ _ 
o Elderly relatives 
• How many? ____ _ 
0 No 
7 
26. Thinking of all the family members in your household, last year in which 
category was your 'before tax' household income? Please include income 
from all sources such as wages, pensions, rent and employment 
insurance. 
0 Less than $10,000 
0 Between $10,000 and $19,999 
0 Between $20,000 and $29,999 
0 Between $30,000 and $39,999 
0 Between $40,000 and $49,999 
0 Between $50,000 and $59,999 
0 Between $60,000 and $69,999 
0 More than $70,000 + 
27. Besides MCP (Medical Care Plan), do you have any other health 
insurance? 
0 Yes 
0 No 
28. Are you part of group insurance (through employer) or private insurance? 
0 Yes 
0 No 
29. Are you a member of a support group? 
0 Yes 
If yes, is your participation of any benefit to you? 
o Yes 
o No 
0 No 
30. Do you have any other comments you would like to add? 
You have now completed the survey. Please return it in the envelope provided. 
If you would like to have a copy of the study results, please complete the 
postcard and mail it separately. 
Thank you for taking part in this study! 
8 
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Prostate cancer patients' out-of-pocket costs 
Researchers at Memorial University of Newfoundland are surveying 
men with prostate cancer to find out how much prostate cancer 
patients pay for their care and how they cope with these costs. We 
also want to know how these costs affect their quality of life and 
decisions about their care treatment. 
This survey will take roughly 20 minutes to complete. The survey is 
voluntary. Whether or not you choose to participate will not affect 
your treatment in any way. All answers are confidential and you will 
not be identified in any report or presentation. You do not have to 
answer every question. 
If you would like to take part in this study, please fill in the survey and 
return it in the envelope provided. If you do not want to participate 
please return the blank survey in the envelope. 
The number on this survey allows us to determine how many surveys 
have been completed. It is not used to identify you. 
If you have any questions or would like information on available 
support programs please contact Emma Hausser at (709) 777-4657 
or by e-mail at Emma Housser@hotmail.com 
Thank you for your assistance with this project. 
Human Investigation Committee 
Research and Graduate Studies 
Faculty of Medicine 
The Health Sciences Centre 
Telephone: 709 777-6974 
Fax: 709 777-8776 
E-mail: hic@mun.ca 
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Research Summary Mail-out Form 
If you are interested in receiving a copy of the summary from 
this study once completed please fill out the address card. 
This form will not be associated with your survey in any way 
and will be kept separately from the collected data. Your 
contact information will not be linked or used for any other 
purpose than to send you a copy of the summary once 
complete. 
Thank you once again for taking part in this survey. 
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UNIVERiiiTY 
Famlty of Medicine 
Dh·i~ion of Community Health and Hum.tnitie~ 
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Date 
Dear survey recipient: 
Researchers at Memorial University are working with the Canadian Cancer Society and 
cancer care providers to study the amount of money patients pay out of their own pocket 
for their cancer care and how they cope with these costs. We also want to know how 
these costs affect your quality of life and decisions about your care treatment. The study 
findings wi11 help improve cancer services in the province. I hope you will take a few 
minutes to fill out and return the survey. 
You have received a survey because your name was included on the Cancer Registry, a 
listing of people diagnosed with cancer each year. We have taken a number of steps to 
ensure that your personal information (such as your name, address or cancer diagnosis) 
are kept confidential. We will not share this infonnation with anyone. 
This survey will take roughly 15-20 minutes to complete. The survey is voluntary. 
Whether or not you choose to participate will not affect your treatment in any way. All 
answers are confidential and you will not be identified in any report or presentation. You 
do not have to answer every question. 
If you would like to take part in this study, please fill in the survey and return it in the 
envelope provided. If you do not want to participate please return the blank survey in the 
envelope. 
If you have any questions about this study, please feel free to contact me at (709) 777-
7845 or the Human Investigations Committee at (709) 777-6974 or hic@mun.ca (please 
cite reference 07.37 or 07.18) 
Thank you for your help with this important study! 
Sincerely, 
Maria Mathews, PhD 
Associate Professor Health Policy/Health Care Delivery 
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Prostate Cancer 
Patients: 
Concerned about drug 
and travel costs? 
Researchers from Memorial University are 
looking for prostate cancer patients to 
complete a brief survey. This study will 
help us understand how much prostate 
cancer patients pay for their care, and how 
these costs affect them. 
For more information, or to request a 
survey, please contact: 
Emma Housser (Masters' candidate 
AHSR) 
(709)777-8539 
emma_housser@hotmail. com 
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Appendix E: Survey variables and coding scheme 
Variable Name Q# Category Codes 
Diagnosis (Ox_ Date) Ql Month Numeric 
Year 
Stage (Dx _Stage) Q2 String 
First Diagnosis (Dx_Fir) Q3 No 0 
Yes 
Currently being treated for other Q4 No 0 
types of cancer ( Dx _ oth) Yes 1 
Type of treatment currently Q5 Radiation O=no 
rece1vmg Hormonal therapy 1=yes 
Chemotherapy 
No active treatment; regular 
follow-up 
Other treatment 
Active or follow up 
Type of treatment previously Q6 Radiation O=no 
had Hormonal therapy 1=yes 
Chemotherapy 
Surgery 
Surgery- prostatectomy 
Surgery - TURP 
Surgery- orchiectomy 
Surgery- other 
Surgery- specify 
Other treatment 
How long have you been Q7 Less than 3 months 0 
receiving treatment 3 and 6 months 1 
Between 6 months and 1 year 2 
Taking part in clinical trials for Q8 No 0 
cancer treatment Yes 
Indicate OOP costs for last Q9 Prescription drugs for prostate $amount 
month and last three months cancer for 1 and 3 
Over the counter drugs for months 
prostate cancer 
Natural or alternative 
medications 
Gas and/or Rental Car 
Bus/taxi 
Plane tickets 
Other transport 
Hotel 
Motel 
Hostel 
Other lodging 
Meals while at the cancer clinic 
Costs for companion/escort 
Communication while at the 
cancer clinic 
Parking (at the cancer clinic) 
Supplies (such as bandages etc) 
Care for a child/ or elder 
Lost wages 
Other costs 
How did costs this month QJO More than other months 0 
compare to other months Similar to other months 1 
(cost_ com) Less than other months 2 
How did you pay for costs Qll Savings O=no 
Help or loan from family/friends l=yes 
Sold belongings 
Fundraiser 
Drugs taking in relation to 
cancer treatment 
Drugs covered by insurance 
Know about MT AP 
-if yes, planning to apply 
Coping strategies 
Ql2 
Q13 
Ql4 
Ql5 
Bank loan 
Social Assistance/Income 
support 
Veteran's benefits 
Medical Transportation 
Assistance program 
Other assistance program from 
cancer clinic or hospital 
Other 
No 
Yes 
No 
Yes 
No 
Yes 
-Spread out a medication over a 
longer period of time to make it 
last longer 
-Replaced the medication your 
doctor prescribed with another 
cheaper one 
-Skipped one or more dose of 
medication to save on costs 
-Bought only what you thought 
was the most important 
medication 
-Not filled a prescription 
because of the cost 
-Delayed filling a prescription 
String 
0 
I 
0 
1 
0 
!=never 
2=not very 
often 
3=some of 
the time 
4=most of 
the time 
5= all ofthe 
time 
How much do you agree or 
disagree with this statement 
because of the cost 
-Asked my doctor for free 
samples of a drug 
-Spread out the time between 
visit to the doctor for follow-up 
visit 
-Missed or cancelled an 
appointment with the cancer 
clinic to save money 
-Missed or cancelled scheduled 
cancer treatment to save money 
Q16 -My out-of-pocket costs 1 =strongly 
influenced my decisions about disagree 
how to treat my prostate cancer 2=disagree 
-My cancer doctor is aware of 
my out-of pocket costs for my 
prostate cancer 
-My doctor takes costs into 
account when prescribing drugs 
forme 
-My cancer related costs create a 
lot of stress 
-Cancer costs create more stress 
for me than other sources of 
stress in my life 
- I am having trouble paying for 
my cancer costs 
- I am aware of assistance 
programs to help me with cancer 
costs 
- All prescription drugs should 
3= neither 
agree or 
disagree 
4=agree 
5=strongly 
agree 
Fact-P statements on well being 
Physical 
Social 
Q17 
be free to everyone, regardless 
of their income 
- All prescription drugs should 
be free to people with low 
mcome 
- Assistance programs are well 
advertised. 
- I have a lack of energy 
- I have nausea 
- Because of my physical 
condition, I have trouble meeting 
the needs of my family 
-I have pain 
- I am bothered by side effects of 
treatment 
- I feel ill 
- I am forced to spend time in 
bed 
- I feel close to my friends 
- I get emotional support from 
my family 
-I get support from my friends 
- My family has accepted my 
illness 
- I am satisfied with family 
communication about my illness 
- I feel my friends and 
acquaintances avoid me. 
- I feel close to my partner (or 
the person who is my main 
support) 
1 =not at all 
2=a little bit 
3=somewhat 
4=quite a bit 
5=very 
much 
l=not at all 
2=a little bit 
3=somewhat 
4=quite a bit 
5=very 
much 
Emotional 
Functional 
Additional concerns 
- I am satisfied with my sex life 
- Refused question on sexual 
activity 
-I feel sad 
- I am satisfied with how I am 
coping with my illness 
- I am losing hope in the fight 
against my illness 
- I feel nervous 
- I worry about dying 
- I worry that my condition will 
get worse 
- I am able to work (include 
work at home) 
- My work (include work at 
home) is fulfilling 
- I am able to enjoy life 
-I have accepted my illness 
- I am sleeping well 
- I am enjoying the things I 
usually do for fun 
- I am losing weight 
- I have a good appetite 
- I have aches and pains that 
bother me 
- I have certain parts of my body 
where I experience significant 
pam 
- My pain keeps me from doing 
things I want to do 
- I am satisfied with my present 
1 =not at all 
2=a little bit 
3=somewhat 
4=quite a bit 
S=very 
much 
1 =not at all 
2=a little bit 
3=somewhat 
4=quite a bit 
S=very 
much 
1 =not at all 
2=a little bit 
3=somewhat 
4=quite a bit 
S=very 
much 
Year ofbirth 
Place of residence 
Postal Code 
Current employment 
Did work situation change 
Q18 
comfort level 
- I am able to feel like a man 
- I have trouble moving my 
bowels 
- I have difficulty urinating 
- I urinate more frequently than 
usual 
- My problems with urinating 
limit my activities 
- I am able to have and maintain 
an erection 
Q19 Town or city 
Q20 
Numeric 
String 
String 
Q21 Full time 0 
P~time 1 
Self-employed 2 
Seasonal/EI 3 
Sick Leave/Paid long term 4 
disability 
Strike 5 
Unemployed 6 
Semi-retired 7 
Retired 8 
Caring for someone-full time 9 
Homemaker 
Student 
Other 
Q22 No 
10 
11 
12 
0 
because of cancer Yes 
Working less 
Working more O=No 
Went back to work 1=Yes 
Quit during treatment 
Leave during treatment 
Level of education Q23 Did not complete high school 0 
Completed high school 
Some post-secondary 1 
Completed post-secondary 2 
Post grad-or professional 3 
training 
4 
Marital Status Q24 Married/living with partner 0 
Single- divorced/separated 
Single- never married 1 
Single - widower 
2 
3 
Caring for children or elderly Q25 No 0 
relatives Yes 1 
Elderly 0 
How many numenc 
Children 
How many numenc 
Household income Q26 >$10,000 0 
$10,000-$19,999 1 
$20,000-$29,999 2 
$30,000- $39,999 3 
$40,000-$49,999 4 
$50,000- $59,999 5 
$60,000- $69,999 6 
<= $70,000 7 
Health insurance other than mcp Q27 No 0 
Yes 1 
Group or private insurance Q28 No 0 
Yes 
Support Group member Q29 No 0 
Yes 
IF yes, is participation helpful No 0 
Yes 
Comments Q30 String 
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Category Specific drug/supplement names 
Vitamins Bl2 
c 
D 
Calcium 
Lycopene 
Glucosamine 
Hormonal Bicalutamide (Casodex ®) 
Cyproterone 
Leuprolide (Eligard®, Lupron ®) 
Goserelin (Zoladex®) 
Bicalutamide (Casodex ®) 
Buserelin (Suprefact®) 
Triptorelin (Trelstar®) 
Cyproterone (Androcur®) 
Docetaxal 
Mitoxantrone 
Supportive prescription drugs Tadalafil (Cialis®) 
Demerol 
Ditropan (Detrol®) 
Tamsulosin (Flomax®) 
Oxybutin (Oxytrol®) 
Sildenafil (Viagra®) 
Docusate 
Terazosin 
apo-bisacodyl 
Ibuprofen (Advil®) 
Hydrocortisone (Anusol HC®) 
Zoledronic acid (Zometa®) 
Oxycodone 
Other Metropolol (Lopresor ®) 
Indomethacin (Indocid®) 
Ramipril (Aitace®) 
Felodipine 
Prednisone 
omeprazole/losec 
Ciprofloxacin 
nifedipine (Adalat ®) 
Pomegranate 
Pravastatin 
exetrol/ezetimibe 
Zopiclone 
ASA 
Hydrochlorothiazide/lisinopril 
(Zestoretic®) 
finasteride (Proscar®) 
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Human Investigation Committee 
Research and Graduate Studies 
Faculty ol Medicine 
The Health Sciences Centre 
January 23, 2007 
Reference #07.18 
Ms. Emma Hausser 
c/o Dr. M. Mathews 
Division of Community Health & Humanities 
Faculty of Medicine 
2nd Floor, Health Sciences Centre 
Dear Ms. Hausser: 
Your application entitled "Prostate cancer patients out-of-pocket costs of cancer and the 
effects on treatment decisions" was reviewed by the Human Investigation Committee at the 
meeting held on January 18,2007. The Committee granted approval of the application 
subject to a satisfactory response to the following: 
(i) The Committee requested additional information on what the potential 
participants will be told when handed the surveys. 
With respect to the cover letter and poster, the Committee requested specific modifications, 
which will be outlined in a letter to the investigator. Please forward a copy of the documents, 
with changes highlighted to the HIC Office for review. 
The Committee agreed that the response and revised documents could be reviewed by the 
Co-Chairs and, if found acceptable, full approval of the study be granted. 
Please be advised that a response to the aforementioned concerns is expected within three 
months of the date of this correspondence. If we do not receive a response within this 
timeframe, the file will be automatically closed by the Co-chairs of the Committee. 
We look forward to hearing further from you regarding the above outlined issues. 
Sincerely, 
John D. Harnett, MD, FRCPC 
Co-Chair 
Human Investigation Committee 
JOH;RSN\jglc 
tc 1ard S. Neuman, PhD 
Co-Chair 
Human Investigation Committee 
SL John's. NL. Canad.1 AlB 3V6 • Tel.: 1709) 777-6974 • Fax: 1709l 777-8776 • email: hic@mun.c.a • www.med.mun.ca/hic 
Prostate cancer patients' out-of-pocket costs 
G~pla.,-,_ w~ ~~ c4J · · · 
@re surveying men with prostate cancer to find out how much 
prostate cancer patients pay for their care, how they cope with these 
costs. We also want to know how these costs affect their quality of 
life and decisions about their care treatment. a.K.. l t:>"-jt/ 
1s- J...R> 'L\ .1 ~ ,.. w\\t t t, 
..., yV\\~ t.,.().~\ .J 
This survey will take rough I 1 0 inutes to complete. The survey is 
voluntary. Whether or not y u choose to participate will not affect 
your treatment in any way. All answers are confidential and you will 
not be identified in any report or presentation. You do not have to 
answer every question. 
If you would like to take part in this study, please fill in the survey and 
return it in the envelope provided. If you do not want to participate 
please return the blank survey in the envelope. 
~u.S to 
The number on this survey allows determine how many surveys have 
been completed. It is not used to identify you. 
If you have any questions, please contact Emma Hous~e~at (709) 
777-4657 or by e-mail at Emma Housser@hotmail.com/ 
Thank you for your assistance with this project. MCl$tev 's S-tu"et"\...t"'· 
~SGY" b \1- ~<:, lJ) vU: o.. c.k 
\.V\ fov MO...tt.otv ht:..re... 
Prostate Cancer 
Patients: 
Concerned about drug 
and travel costs? 
Researchers from Memorial University are 
looking for prostate cancer patients to 
complete a brief survey. This study will 
help us understand how much prostate 
cancer patients pay for their care, and how 
these costs affect them. 
For more information, or to request a 
survey, please contact: 
6fdd.~n.t Emma Hotisser (Masters' ..canidate 
AHSR) 
(709)777 -8539 
emma_ housser@hotmail.com 
Human Jnvestigat10n Committee 
Research and Graduate Studies 
Faculty of Medicine 
The Health Sciences Centre 
March 7, 2007 
Reference #07.18 
Ms. Emma Hausser 
c/o Dr. M. Mathews 
Division of Community Health & Humanities 
F acuity of Medicine 
2"d Floor, Health Sciences Centre 
Dear Ms. Hausser: 
"Prostate cancer patients out-of-pocket costs of cancer and the effects on treatment 
decisions". 
This will acknowledge your correspondence dated, March 6, 2007, wherein you provide the 
following for the above noted study: 
o Cover Jetter 
o Poster 
o Additional infonnation on what potential participants will be told when handed the 
surveys 
o Instructions to prostate cancer support group managers 
At the meeting held on January 18, 2007, the initial review date of this study, the Human 
Investigation Committee (HIC) agreed that the response could be reviewed by the Co-Chairs 
and, if found acceptable, full approval ofthe study be granted. 
The Co-Chairs of the HIC reviewed your correspondence, approved the cover letter, poster and 
instructions to prostate cancer support group managers and, under the direction of the 
Committee, granted full approval of your research study. This will be reported to the full 
Human Investigation Committee, for their information at the meeting scheduled for. 
Full approval has been granted for one year. You will be contacted to complete the annual 
fom1 update approximately 8 weeks before the approval will lapse on January 18, 2008. It is 
your responsibility to ensure that the renewal form is forwarded to the HIC office not less than 
30 days prior to the renewal date for review and approval to continue the study. The annual 
renewal fom1 can be downloaded from the HIC website 
http://www.med.mun.ca/hic/downloads/Annuai'Yo20Update%20Form.doc. 
The Humall Investigation Committee advises THAT IF YOU DO NOT retum the completed 
annual update form prior to or 011 tire a(oreme11tioned date o(reuewal; 
St. John'$, NL. Canada AlB 3V6 • Tel.: (709) 777-6974 • Fax: (709) 777-8776 • email: hic@mun.ca • wwwmcd.mun.calhic 
The Humau Investigation Committee advises THAT IF YOU DO NOT 1·etum tire completed 
mmual update form prior to or ou the aforementioned date o(reuewal; 
* Your ethics approval will/apse 
* 
* 
You will be required to stop research activity 
You will not be permitted to restart the study until you reapply for and receive 
approval to undertake the study again 
In addition. tfte Human lttvestigation Committee will inform the ap,orouriate authorities. To 
ensure uraver action is tqken; tlte QJlpragriate o(ficials will be notified to tenninate fumline. 
Modifications of the protocol/consent are not permitted without prior approval from the 
Human Investigation Committee. Implementing changes in the protocol/consent without 
HIC approval may result in the approval ofyour research study being revoked, 
necessitating cessation of all related research activity. Request for modification to the 
protocol/consent must be outlined on an amendment form (available on the HIC website) 
and submitted to the HIC for review. 
For a hospital-based study, it is your responsibility to seek the necessarv approval from the 
Health Care Corporation of St. John's and/or other hospital boards as appropriate. 
This Research Ethics Board (the HIC) has reviewed and approved the application and consent 
form for the study which is to be conducted by you as the qualified investigator named above 
at the specified study site. This approval and the views of this Research Ethics Board have 
been documented in writing. In addition, please be advised that the Human Investigation 
Committee currently operates according to the Tri-Council Policy Statement and applicable 
laws and regulations. The membership of this research ethics board complies with the 
membership requirements for research ethics boards defined in Division 5 of the Food and 
Drug Regulations. 
Notwithstanding the approval of the HIC, the primary responsibility for the ethical conduct of 
the investigation remains with you. 
We wish you every success with your study. 
Sincerely, 
John D. Harnett, MD, FRCPC 
Co-Chair 
Human Investigation Committee 
JDH;RSN\jed 
RichardS. Neuman, PhD 
Co-Chair 
Human Investigation Committee 
C Dr. C. Loomis, Vice-President (Research), MUN 
Mr. W. Miller, Director of Planning & Research, Eastern Health 
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Eastern 
Health 
April 23, 2007 
Ms. E. Houser 
Community Medicine 
cfo Dr. Maria Mathews 
Associate Professor 
Health Policy/Health Care Delivery 
MUN 
Dear Ms. Houser: 
St. Clare's Mercy Hospital 
St. John's, NL 
Canada A 1 C 5B8 
T: (709) 777-5233 
F: (709) 777-5272 
www.eastemheal!h.ca 
Your research proposal "H/C # 07.018- Prostate cancer patients' out-of-pocket costs and the 
effects on treatment decisions" was reviewed by the Research Proposals Approval Committee 
(RPAC) of Eastern Health at its meeting on April19, 2007 and we are pleased to inform you that 
the proposal has been approved. 
The approval of this project is subject to the following conditions: 
• The project is conducted as outlined in the HIC approved protocol; 
• Adequate funding is secured to support the project; 
• In the case of Health Records, efforts will be made to accommodate requests based 
upon available resources. If you require access to records that cannot be 
accommodated, then additional fees may be levied to cover the cost; 
• A progress report being provided upon request. 
If you have any questions or comments, please contact Lynn Purchase, Manager of the Patient 
Research Centre at 777-7283. 
Sincerely, 
~ 
Mr. Wayne Miller 
Senior Director Corporate Strategy & Research 
Chair, RPAC 
Eastern Health 
cc: Ms. Lynn Purchase 
Dr. Maria Mathews, Associate Professor, Health Policy/Health Care Delivery, MUN 
Appendix J 
Provincial Cancer Centre RPAC 
129 
MSN Hotmail - rage 1 01 ' 
emma __ housser@hotmail.com Pnnted: July 4, 2007 10:06:52 AM 
From: 
Sent: 
To: 
cc: 
Subject: 
Joy McCarthy <joys.mccarthy@gmail.com> 
May 15, 2007 12:14:17 PM 
"Dawne Putt" <Dawne.Putt@easternhealth.ca> 
<emma_housser@hotmall.com> 
Re: ·sAC application-· 
Hi Dawne - I already approved this and stamped it - no idea where it went! 
----""-· . _.., ... --.,_--,.------··----··~--- .... ~~ --- ... -~"" ..... _.., ,...__.,..~ .. ""·--- .. ---·---~---.. -
Emllla oan keep this· l!lltatl"IUI proof of -&ppZ'4Vail-. ·-l··bave-~rov~ it anywa.ysl I re~d thru the · 
material - it maybe on my desk and got waylaid when Julia was want;ing to be fed). 
~~-;~;;;--;;~;;-;~;;;dT Good luck with your project I 
Joy 
Original Message ----- From: "Dawne Putt" <Dawne.Putt@easternhealth.ca> 
To: "Joy McCarthy" <joys.mccarthy@gmail.com> 
Sent: Monday, May 14, 2007 11:23 AM 
Subject: FW: SAC application 
Hi Joy, 
Emma Hausser has a study she has been waiting to have approved at the 
next SAC meeting. She has called a couple of times to find out the 
status or the date. Since we do not know when the next meeting is, as 
we are waiting for more information from the studies that have been 
proposed; could you review this? 
Thanks 
Dawne 
-----Original Message-----
From: Emma Heusser !mailto:emma_housser@hotmail.coml 
Sent: Monday, May 14, 2007 11:13 AM 
To: Dawne Putt 
cc: mmathews@mun.ca 
Subject: SAC application 
Dawne, 
As discussed earlier today, I have included the Application letter for 
SAC as well as the supporting documents. Please let me know if any 
other documents are required for this process. 
Thank you for your help, 
Emma 
Emma Hausser 
Master's student, Applied Health Services Research Division of Community 
Health and Humanities, Faculty of Medicine 
Windows Live Hotmail with drag and drop, you can easily move and 
organize your mail in one simple step Get it today! 
<http:/ /g.msn.com/BH MBENCA/2752??PS=47575 > 
http://by120fd.bayl20.hotmail.msn.com/cgi-bin!getmsg?curmbox=6051 E9BF%2d8300%2d... 7/4/2007 
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'•,.' . (l ' •. 
Dec·.:mber I~- 2007 
Rct'ercncc #07.18 
\1s. Elllma Housser 
c,'o Dr. .\1. Mathews 
Di\ r:>ion of Community Health & Humanities 
F:1cultv of Medtcine 
2"" Fl(;or, Health Sciences Centre 
Dear :Yis. Hous:;cr: 
r-.,r f.' f' opv r 1.uL v · 1 
ENTERED DEC 1 8 2007 
II' SHIPPED DEC 1 C 2007 
This\\ rll :1dnowledge your completed amendment form dated '\ovember 21, 21J0 7 \\·h<:rein you :111 
,lmer•dment. cover letter and survey. for your research study entitled ··Prostate cam·er patknts out-of-
pocket costs of cancer and the effects on treatment decisions" 
The Chair-; of the Human Investigation Committee have revie,ved your correspondence. appro' eel the 
amendment, cover letter and ~urvey, as submitted. This will be reported to the full Human ln'vestigation 
Committee. for their information. at the meeting scheduled for .January I 0, 2008. 
Thi~ Research Ethics Board (the HI C) has reviewed and approved the amendment for the :;tudy '' hich 
rs to he conducted by you as the qualified investigator named above at the ~peciticd study ~It<:. Thi~ 
appto,·:~l and the view:; ofth1s Research Ethics Board have been documented 111 \Hiting. In addrtion. 
please be advised that the Human Investigation Committee currently operates accordtng to the Tri-
Council Policy Statement and applicable laws and regulations. The memb~rshir of this re:-,earch ethic:-. 
board complies with the membership requtrements for research ethics hoards Jetinc>d in Di' i~ion 5 of 
the Food and Drug: Regulations. 
R1ch~•rcl '\:cum;ln. PhD 
( O-( hclir 
Hum.1n Ill\ .:~ti:.;.tt•on Committee 
John Harnett. \1 D. FRCPC 
Co-Chair 
Human In\ ~~trg.nion C,1mmirrec 
C Dr. C. Loomrs. \"ice-President !Rese:-~r(:h). \!l '\ 
\ l1 \\a: n~· \I i lkr. Director of Pbnning & Resc·arch, HCCS.I 
Human InvestJ..gation Committee-_-. ··. • i· · Request for Amendment to an approved applJ.cation 
'< \ I : ~\ ~ ,' . ~ , · ... 
.. ~ ... \ \ \. 1.. ~ 
·f>Tfif~ forln not to e~~~ed one page in length. 
/~ ~>- .......... " . . : ~ <It • , ... -:~\ 
Forward I copy of this fonn and ~liot~ for'the··amendmetTt ~\Human Investigation Committee, Room I 755, Health Science 
Centre. . ·· · 1 • · :·:·.\ ~.._-. Dt1 : . 
\.-
Title of study. Include protocol ~tiinber, 1f any. 
'i. 
· --~·-. HIC number: 07.18 Date· Nov 21, 2007 
' ~~~~;~~~5cancer patJ..ents:o~~ of-pocket~~~~ of cancer and the effects on treatment ~f'PROVED OEC 1 2 2001 
all 
Would you categorize the changes as minor (e.g. editorial, administrative and similar changes) Yes No 
Will there be any increase in risk, discomfort or inconvenience to the participants? Yes (Specify below) No 
Are there changes to inclusion or exclusion criteria? Yes (Specify below) No 
Is a modification to the consent form required? Yes (Append form) No 
Are there any significant changes to the original objectives? YES NO If so, LIST new objectives. 
1 To ... 
What ts the rationale for the amendment(s)? 
Of the 64 surveys we have received to date, only I 6 surveys are from recently diagnosed men (i.e. diagnosed within the last 18 
months). Most costs are experienced during active treatment (i.e. chemotherapy and radiation) which is done soon after diagnosis. 
Additional surveys from recently diagnosed patients are needed to obtain credible results. 
Summarize the significant changes being requested. It is not necessary to itemize editorial, administrative and similar changes. 
We will send a mailed survey to men who were diagnosed with prostate cancer in preceding year (i.e. December 2006). The men 
will be identified through the cancer reg1stry. The registry will provide names and addresses to a research assistant (Sarah 
Wickham) who will prepare mailing labels and ma1l the survey (and then destroy the list of names and addresses). We will not use 
identification numbers and surveys will not be linked back to names from the registry (thereby protecting anonymity). None ofthe 
investigators will have access to the names. 
Other pertinent information. 
Survey package will include: cover letter from Dr. Mathews, survey, form to request study results, and return envelope (attached) 
PrJ..nted Name of Pr1ncipal Investigator Signature of Principal Investigator Date 
UNIVERSITY 
Faculty of Medicint' 
Divi.~ion of Community Health and Humanities 
r q~ Hr nl' h s-- Pnrr·s r ..... n•rr· 
0' , or'r, s f'-~L C<1r'dC.L1 A i B ~~VA 
ir ,'!]0 /77 6?~ ~/AI:;) F, 7 70-i J7 / 138) WI.VW rned mun cu 
Date 
Dear survey recipient: 
Researchers at Memorial University are working with the Canadian Cancer Society and 
cancer care providers to study the amount of money patients pay out of their own pocket 
for their cancer care and how they cope with these costs. We also want to know how 
these costs affect your quality of life and decisions about your care treatment. The study 
findings will help improve cancer services in the province. I hope you will take a few 
minutes to fill out and return the survey. 
You have received a survey because your name was included on the Cancer Registry, a 
listing of people diagnosed with cancer each year. We have taken a number of steps to 
ensure that your personal information (such as your name, address or cancer diagnosis) 
are kept confidential. We will not share this information with anyone. 
This survey will take roughly 15-20 minutes to complete. The survey is voluntary. 
Whether or not you choose to participate will not affect your treatment in any way. All 
answers are confidential and you will not be identified in any report or presentation. You 
do not have to answer every question. 
If you would like to take part in this study, please fill in the survey and return it in the 
envelope provided. If you do not want to participate please return the blank survey in the 
envelope. 
If you have any questions about this study, please feel free to contact me at (709) 777-
7845 or the Human Investigations Committee at (709) 777-6974 or hic@mun.ca (please 
cite reference 07.37 or 07. t 8) 
Thank you for your help with this important study! 
Sincerely, 
Maria Mathews, PhD 
Associate Professor Health Policy/Health Care Delivery 
Research Summary Mail-out Form 
If you are interested in receiving a copy of the summary from 
this study once completed please fill out the address card. 
This form will not be associated with your survey in any way 
and will be kept separately from the collected data. Your 
contact information will not be linked or used for any other 
purpose than to send you a copy of the summary once 
complete. 
Thank you once again for taking part in this survey. 
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Appendix L. Representativenesss of Sample 
Table Kl. Comparison on community type and age of sample and population of prostate 
cancer patients 
Characteristic Sample Prostate Cancer Population p value 
n (%) n(%) 
Age* >0.05 
<50 3 (1.8) 64 (2.8) 
50-59 25 (14.7) 466 (20.6) 
60-69 86 (50.6) 946(41.8) 
70-79 47(27.6) 607 (26.8) 
> 80 9 (5.3) 180 (8.0) 
Community Type** >0.05 
Urban 78 (45.9) 206 (50.2) 
Rural 92(54.1) 204 (49.8) 
* 
,l_ 
-age based on five years (2004-8) of Cancer Regtstry data, X- 8.08, degrees of freedom- 4 
** community types based on sample frame addresses; X2= 1.15, degrees of freedom= 1 
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Ml. OOP Costs (dollar value) in last month 
Cross tabulations and chi-square test results for the comparison of demographic 
characteristics and the three levels of cost categories (dollar amount in last month) are 
displayed in Table Ml. Compared to men with no costs, a larger proportion of rural 
patients had costs up to $500 and more than $500. 
Table Ml. Level ofOOP costs (dollar amount) for the All Costs category in a one month 
period and demographic characteristics. 
Characteristic $0 $0.01 - ~$500.00 
n (%) $499.99 n (%) p value 
n (%) 
Age (n = 170) 
< 65 39 (41.1) 17 (33.3) 10 (41.7) 0.629 
> 65 56 (58.9) 34 (66.7) 14 (58.3) 
Community Type (n = 170) 
Urban 51 (53.7) 23 (45.1) 4 (16.7) 0.005* 
Rural 44 (46.3) 28 (54.9) 20 (83.3) 
Marital Status (n = 165) 
Un-partnered 11 (12.2) 6 (11.8) 3 (12.5) 0.995 
Partnered 79 (87.8) 45 (88.2) 21 (87.5) 
Dependents (n = 164) 
Yes 18(19.4) 8 (16.7) 6 (26.1) 0.643 
No 75 (80.6) 40 (83.3) 17 (73.9) 
Employment Status (n = 169) 
Full-Time/self-employed 12 (12.6) 5 (9.8) 1 (4.3) 
Part-Time/semi-retired 6 (6.3) 4 (7.8) 4 (17.4) 0.667 
Seasonal/sick 8 (8.4) 4 (7.8) 2 (8.7) 
leave/unemployed/other 
Retired 69 (72.6) 38 (74.5) 16 (69.6) 
Education (n = 166) 
Less than high school 28 (30.8) 16 (31.4) 12 (56.0) 
Completed high school 20 (22.0) 11 (21.6) 3 (12.5) 0.589 
Some post secondary 13 (14.3) 7 (13.7) 4 (16.7) 
Completed post secondary 19 (20.9 10(19.6) 1 (4.2) 
Graduate/professional degree 11 (12.1) 7 (13.7) 4 (16.7) 
Income (n = 170) 
< $19,999 12 (12.6) 6 (11.8) 6 (25.0) 
$20,000 - $29,999 22 (23.3) 11 (21.6) 5 (20.8) 
$30,000 - $39,999 19 (20.0) 9 (17.6) 5 (20.8) 0.959 
$40,000 - $49,999 13 (13. 7) 9 (17.6) 3 (12.5) 
$50,000 - $59,999 12 (12.6) 6 (11.8) 1 (4.2) 
$60,000 - $69,999 5 (5.3) 3 (5.9) 2 (8.3) 
> $70,000 12 (12.6) 7 (14.7) 2 (8.3) 
Have Private Insurance (n = 161) 
Yes 60 (68.2) 32 (65.3) 12 (50.0) 0.254 
No 28 (31.8) 17 (34.2) 12 (50.0) 
Know about MTAP (n = 139) 
Yes 28 (38.4) 17 (39.5) 11 (47.8) 0.717 
No 45 (61.6) 26 (60.5) 12 (52.2) 
Table M2 displays cross-tabulations and chi-square test results comparing the 
clinical characteristics and cost categories ofOOP costs (dollar amounts). Compared to 
men with costs less than $500, a larger portion of men with costs greater than $500 had 
previously received radiation treatment. A larger proportion of men with costs reported 
taking supportive drugs than men without costs. Compared to men with either no costs or 
with $500 or more, a larger proportion of men who had cost between 0 and $499.99 
reported taking vitamins and supplements. 
Table M2. Level of OOP costs (dollar amount) for the All Costs category in a one month 
period and clinical characteristics. 
Clinical Characteristics $0.01 ~ 
$0 $499.99 ::::$500.00 
n (%) n (%) n (%) p value 
Time Since Diagnosis (n = 167) 
0-6 months 21 (22.6) 10 (20.0) 1 (4.2) 
7- 12 months 28 (30.1) 21 (42.0) 9 (37.5) 0.249 
13 - 24 months 21 (22.6) 9 (18.0) 9 (37.5) 
24 months+ 23 (24.7) 10 (20.0) 5 (20.8) 
Current Treatment (n = 170) 
Radiation 
Yes 8 (8.4) 6 (11.8) 5 (20.8) 0.223 
No 87 (91.6) 45 (88.2) 19 (79.2) 
Hormone Therapy 
Yes 11 (11.6) 11 (21.6) 6 (25.0) 0.143 
No 84 (88.4) 40 (78.4) 18 (75.0) 
Chemotherapy 
Yes 0 (0.0) 0 (0.0) 0 (0.0) .a 
No 95 (100.0) 51(100.0) 24(100.0) 
Active Treatment 
Yes 34 (35.8) 18 (35.3) 10 (41.7) 0.848 
No 61 (64.2) 33 (64.7) 14 (58.3) 
Other 
Yes 11 (11.6) 2 (3.9) 3 (12.5) 0.273 
No 84 (88.4) 49 (96.1) 21 (87.5) 
Active Treatment or Follow-up 
Yes 24 (25.3) 14 (27.5) 8 (33.3) 0.727 
No 71 (74.7) 37 (72.5) 16 (66.7) 
Past treatment (n = 169) 
Radiation 
Yes 24 (25.3) 13 (25.5) 14 (60.9) 0.003* 
No 71 (74.7) 38 (74.5) 9 (39.1) 
Hormone Therapy 
Yes 10 (10.5) 9 (17.6) 3 (12.5) 0.473 
No 85 (89.5) 42 (82.4) 21 (87.5) 
Chemotherapy 
Yes 1 (1.1) 0 (0.0) 0 (0.0) 0.672 
No 94 (98.9) 51(100.0) 24(1 00.0) 
Surgery 
Yes 49 (51.6) 26 (51.0) 10 (41.7) 0.677 
No 46 (48.4) 25 (49.0) 14 (58.3) 
Prostatectomy 
Yes 41 (43.2) 26 (51.0) 8 (33.3) 0.343 
No 54 (56.8) 25 (49.0) 16 (66.7) 
TURP 0.300 
Yes 3 (3.2) 0 (0.0) 0 (0.0) 
No 92 (96.8) 51(100.0) 24(100.0) 
Orchiectomy 0.197 
Yes 0 (0.0) 1 (2.0) 1 (4.2) 
No 95 (100.0) 50(98.0) 23 (95.8) 
Other 0.309 
Yes 0 (0.0) 1 (2.0) 0 (0.0) 
No 95 (100.0) 50 (98.0) 24(100.0) 
Length of Time Receiving Treatment 0.945 
(n = 75) 
< 3 months 14 (45.2) 11(42.3) 6 (33.3) 
3-6 months 5 (16.1) 4 (15.4) 3 (16.7) 
6 months - 1 year 12 (38.7) 11 (42.3) 9 (50.0) 
Drugs taken (n = 170) 
Hormone Treatment 0.401 
Yes 15 (15.8) 12 (23.5) 6 (25.0) 
No 80 (84.2) 39 (76.5) 18 (75.0) 
Supportive 0.001 * 
Yes 3 (3.2) 11 (21.6) 5 (20.8) 
No 92 (96.8) 40 (78.4) 19 (79.2) 
Vitamins/Supplements 0.036* 
Yes 4 (4.2) 8 (15.7) 1 (4.2) 
No 91 (95.8) 43 (84.3) 23 (95.8) 
Miscellaneous 0.488 
Yes 4 (4.2) 3 (5.9) 0 (0.0) 
No 91 (95.8) 48 (94.1) 24(100.0) 
* Statistically significant; p<0.05 
a. No statistics available as variable is a constant in this instance. 
There were no differences in the use of coping strategies and OOP costs (dollar 
amount), as shown in table M3. 
Table M3. Level ofOOP costs (dollar amount) for the All Costs category in last month 
and use of coping strategies. 
Coping strategies $0.01 -
$0 $499.99 :::::_$500.00 p value 
n (%) n (%) n (%) 
Drug Coping Strategies 
(n == 170) 
Yes 5 (5.3) 7 (13.7) 2 (8.3) 0.208 
No 90 (94.7) 44 (86.3) 22 (91.7) 
Appointment Coping Strategies 
(n = 170) 
Yes 2 (2.1) 2 (3.9) 1 (8.3) 0.330 
No 93 (97.9) 49(96.1) 22 (91.7) 
* Statistically significant; p<0.05 
Likewise, there were no significant differences in quality oflife and OOP costs 
incurred (dollar amount) for a one month period (Table M4). 
Table M4. Level ofOOP costs (dollar amount) for the All Costs category in last month 
and quality oflife. 
Quality of Life $0 $0.01 - $499.99 :::::_$500.00 p value 
mean (sd) mean (sd) mean (sd) 
FACTG Total 
(n = 126) 85.41 (14.381) 8486.36(12.417) 81.00(15.248) 0.344 
FACT PTotal 
(n==126) 117. 79(19.684) 119.26(16.769) 111.33(20.568) 0.286 
* Statistically significant; p<0.05 
Table M5 presents attitudes by amount ofOOP costs. Compared to those who 
reported costs less than $499.99 for a one month period, a larger proportion of 
respondents with costs in excess of $500 found OOP costs influenced treatment 
decisions, that cancer costs created a lot of stress, that cancer costs were more stressful 
than other things and, and they had trouble paying for cancer costs. 
Table M5 Level of OOP costs (dollar amount) for the All Costs category in a one month 
. d d . d d" h peno an athtu es regar mgt ese costs. 
Attitudes $0.01 -
$0 $499.99 ~$500.00 
n (%) n (%) n (%) p value 
OOP costs influenced treatment 
decisions 
Agree 4 (6.5) 0 (0.0) 5 (25.0) 0.002* 
Disagree 58 (93.5) 43 (100.0) 15 (75.0) 
Doctor aware of my OOP costs 
Agree 16(28.1) 7 (17.9) 8 (42.1) 0.145 
Disagree 41 (71.9) 32 (82.1) 11 (57.9) 
Doctor takes costs into account 
Agree 5 (9.3) 5 (12.2) 5 (26.3) 0.163 
Disagree 49 (90.7) 36 (87.8 14 (73.7) 
Cancer costs create a lot of stress 
Agree 13 (22.4) 6 (14.6) 14 (63.3) 0.000* 
Disagree 45 (77.6) 35 (85.4) 8 (36.4) 
Cancer costs more stressful than 
other things 
Agree 11 (19.0) 4 (9.5) 11 (50.0) 0.001 * 
Disagree 47(81.0) 38 (90.5) 11 (50.0) 
Trouble paying for my cancer costs 
Agree 5 (8.8) 3 (7.3) 7 (31.8) 0.010* 
Disagree 52 (91.2) 38 (92.7) 15 (68.2) 
Aware of assistance programs 
Agree 14 (23.7) 12 (28.6) 7 (35.0) 0.603 
Disagree 45 (76.3) 30 (71.4) 13 (65.0) 
Prescription drugs free to everyone 
Agree 40 (63.5) 23(56.1) 15 (65.2) 0.689 
Disagree 23 (36.5) 18 (43.9) 8 (34.8) 
Prescription drugs free to low income 
people 
Agree 57 (86.4) 35 (81.4) 18(81.8) 0.753 
Disagree 9 (13.6) 8 (18.6) 4 (18.2) 
Assistance programs well 
advertised 
Agree 9 (13.4) 5 (11.6) 3 (13.6) 0.956 
Disagree 58 (86.6) 38 (88.4) 19 (86.4) 
* Statistically significant; p<0.05 
M2 Proportion of Income consumed by costs 
The next series of tables examine the relationship between proportion of income 
consumed by OOP costs and demographic and clinical characteristics, use of cost saving 
strategies, attitudes and quality of life. 
The cross tabulations and chi-square test results comparing socio-demographic 
characteristics and proportion of income consumed by OOP costs for a one month period 
are displayed in M6. Compared to men who spent less than 7.5% of their income on 
OOP costs, men who spent 7.5% or more of their income on OOP costs were from rural 
communities and did not have private health insurance. 
Table M6. Percent of income consumed by OOP All costs category in one month period 
and demographic characteristics. 
Characteristic 0.01-
0% 7.49% ~7.50% 
n (%) n (%) n (%) p value 
Age (n = 170) 
< 65 39 (41.1) 12 (30.8) 15 (41. 7) 0.500 
> 65 56 (58.9) 27 (69.2) 21 (58.3) 
Community Type (n = 170) 
Urban 51 (53.7) 20 (51.3) 7 (19.4) 0.002* 
Rural 44 (46.3) 19 (48.7) 29(80.6) 
Marital Status (n = 165) 
Un-partnered 11 (12.2) 4 (1 0.3) 5 (13.9) 0.890 
Partnered 79 (87.8) 35 (89.7) 31 (86.1) 
Dependents (n = 164) 
Yes 18(19.4) 5 (13.9) 9 (25.7) 0.453 
No 79 (80.6) 31 (86.1) 26 (74.3) 
Employment Status (n = 169) 
Full-Time/self-employed 12 (12.6) 5 (12.8) 1 (2.9) 
Part-Time/semi-retired 6 (6.3) 3 (7.7) 5 (14.3) 0.492 
Seasonal/sick 8 (8.4) 2 (5.1) 4 (11.4) 
leave/unemployed/other 
Retired 69 (72.6) 29 (74.4) 25 (71.4) 
Education (n = 166) 0.666 
Less than high school 29 (33.0) 18 (34.6) 9 (34.6) 
Completed high school 16 (18.2) 12 (23.1) 6 (23.1) 
Some post secondary 16 (18.2) 6 (11.5) 2 (7.7) 
Completed post secondary 16 (18.2) 11 (21.2) 3 (11.5) 
Graduate/professional degree 11(12.5) 5 (9.6) 6 (23.1) 
Income (n = 170) 0.214 
<$19,999 12 (12.6) 2 (5.1) 10 (27.8) 
$20,000 - $29,999 22 (23.2) 8 (20.5) 8 (22.2) 
$30,000- $39,999 19 (20.0) 5 (12.8) 9 (25.0) 
$40,000 - $49,999 13 (13.7) 9 (23.1) 3 (8.3) 
$50,000- $59,999 12 (12.6) 5 (12.8) 2 (5.6) 
$60,000- $69,999 5 (5.3) 3 (7. 7) 2 (5.6) 
> $70,000 12(12.6) 7 (17.9) 2 (5.6) 
Have Private Insurance (n = 161) 0.012* 
Yes 60 (68.2) 28 (75.7) 16 (44.4) 
No 28 (31.8) 9 (24.3) 20 (55.6) 
Know about MTAP (n = 139) 0.888 
Yes 28 (38.4) 14 (42.4) 14 (42.4) 
No 45 (61.6) 19 (57.6) 19(57.6) 
* Statistically significant; p<0.05 
Table M7 presents the clinical characteristics of the sample by proportion of 
income consumed by OOP costs in one month. Compared to men who spent either 0% or 
7.5% or more of their income on OOP costs, a larger proportion of men who spent 
between 0.1% and 7.49% of their income on OOP costs took supportive drugs or 
supplements and vitamins. 
Table M7. Percent of income consumed by OOP All costs category in a one month 
period and clinical characteristics. 
Clinical Characteristics 0.01-
0% 7.49% ::::7.50% 
n (%) n (%) n(%) p value 
Time Since Diagnosis (n = 167) 
0-6 months 21 (22.6) 5 (13.2) 6 (16.7) 0.535 
7- 12 months 28 (30.1) 17 (44.7) 13 (36.1) 
13 - 24 months 21 (22.6) 7 (18.4) 11 (30.6) 
24 months+ 23 (24.7) 9 (23.7) 6 (16.7) 
Current Treatment (n = 170) 
Radiation 
Yes 8 (8.4) 3 (7.7) 8 (22.2) 0.060 
No 87 (91.6) 36 (92.3) 28 (77.8) 
Hormone Therapy 
Yes 11 (11.6) 8 (20.5) 9 (25.0) 0.134 
No 84 (88.4) 31 (79.5) 27 (75.0) 
Chemotherapy 
Yes 0 (0.0) 0 (0.0) 0 (0.0) n/a 
No 95 (I 00.0) 39(100.0) 36(100.0) 
Active Treatment 
Yes 34 (35.8) 13 (33.3) 15 (41.7) 0.739 
No 61 (64.2) 26 (66.7) 21 (58.3) 
Other 
Yes 11 (11.6) 2(5.1) 3 (8.3) 0.494 
No 84 (88.4) 37 (94.9) 33 (91.7) 
Active Treatment or Follow-up 
Yes 24 (25.3) 10 (25.6) 12 (33.3) 0.633 
No 71 (74.7) 29 (74.4) 24 (66.7) 
Past treatment (n = 169) 
Radiation 
Yes 24 (25.3) 11 (28.2) 16 (45.7) 0.075 
No 71 (74.7) 28 (71.8) 19 (54.3) 
Hormone Therapy 
Yes 10(10.5) 7 (17.9) 5 (13.9) 0.499 
No 85 (89.5) 32 (82.1) 31 (86.1) 
Chemotherapy 
Yes 1 (1.1) 0 (0.0) 0 (0.0) 0.672 
No 94 (98.9) 39(100.0) 36(100.0) 
Surgery 
Yes 49 (51.6) 20 (51.3) 16 (44.4) 0.754 
No 46 (48.4) 19 (48.7) 20 (55.6) 
Prostatectomy 
Yes 41 (43.2) 19 (48.7) 15 (41.7) 0.795 
No 54 (56.8) 20 (51.3) 21 (58.3) 
TURP 
Yes 3 (3.2) 0 (0.0) 0 (0.0) 0.300 
No 92 (96.8) 39(100.0) 36(100.0) 
Orchiectomy 
Yes 0 (0.0) 1 (2.6) 1 (2.8) 0.277 
No 95(100.0) 38 (97.4) 35 (97.2) 
Other 
Yes 0(0.0) 1 (2.6) 0 (0.0) 0.185 
No 95 (100.0) 38 (97.4) 36(100.0) 
Length of Time Receiving 
Treatment 
(n = 75) 14 (45.2) 8 (40.0) 9 (37.5) 0.848 
< 3 months 5 (16.1) 2 (10.0) 5 (20.8) 
3-6 months 12 (38.7) 10 (50.0) 10 (41. 7) 
6 months - 1 year 
Drugs taken (n = 170) 
Hormone Treatment 
Yes 15 (15.8) 8 (20.5) 10 (27.8) 0.296 
No 80 (84.2) 31 (79.5) 26 (72.2) 
Supportive 
Yes 3 (3.2) 10 (25.6) 6 (16.7) 0.000* 
No 92 (96.8) 29 (74.4) 30 (83.3) 
Vitamins/Supplements 
Yes 4 (4.2) 7 (17.9) 2 (5.6) 0.022* 
No 91 (95.8) 32 (82.1) 34 (94.4) 
Miscellaneous 
Yes 4 (4.2) 3 (7.7) 0 (0.0) 0.245 
No 91 (95.8) 36 (92.3) 36(100.00) 
* Statistically significant; p<0.05 
a. No statistics available as variable is a constant in this instance. 
There were no significant differences in proportion of income consumed by OOP 
costs in a one month period and either use of a coping strategy (Table M8) or quality of 
life scores (Table M9). 
Table M8. Percent of income consumed by OOP All costs category in a quarter (three 
mon th d) d f t t . peno an useo copmg s ra eg1es. 
Coping strategies 0.01-
0% 7.49% ;:::7.50% 
n(%) n (%) n (%) p value 
Drug Coping Strategies 
(n = 170) 
Yes 5 (5.3) 5 (12.8) 4(11.1) 0.274 
No 90 (94.7) 34 (87.2) 32 (88.9) 
Appointment Coping Strategies 
(n = 170) 
Yes 2 (2.1) 2(5.1) 2 (5.6) 0.524 
No 93 (97.9) 37 (94.9) 34 (94.4) 
* Statistically significant; p<0.05 
Table L9. Percent of income consumed by OOP All costs category in a one month period 
and quality of life. 
Quality of Life 0% 0.01-4.99% ;:::7.49% p value 
mean (sd) mean (sd) mean (sd) 
FACTG Total 
(n = 126) 85.41 (14.381) 87.77 (10.828) 80.97 (15.456) 0.157 
FACT PTotal 117.79 (19.684) 120.52 (15.004) 112.17 (20.879) 0.221 
(n=l26) 
* Statistically significant; p<0.05 
Cross tabulations and chi-square test results for attitudes and the cost categories 
(proportion of income consumed) are displayed in table Ml 0. Compared to patients with 
less than 7.5% of their income consumed by OOP costs, a larger proportion of those with 
more than 7.5% of their income consumed agreed that OOP costs influenced treatment 
decisions, that OOP cancer costs created a lot of stress and more stress than other things 
in their lives, and that they had trouble paying for these costs. 
Table M 10. Percent of income consumed by OOP All costs category in a quarter (three 
month period) and attitudes regarding these costs 
Attitudes 0% 0.01- ~7.50% p value 
n (%) 7.49% n (%) 
n (%) 
OOP costs influenced treatment decisions 0.029* 
Agree 4 (6.5) 0 (0.0) 5 (17.2) 
Disagree 58 (93.5) 34(1 00.0) 24 (82.8) 
Doctor aware of my OOP costs 0.472 
Agree 16 (28.1) 6 (19.4) 9 (33.3) 
Disagree 41 (71.9) 25 (80.6) 18(66.7) 
Doctor takes costs into account 0.489 
Agree 5 (9.3) 5 (15.6) 5 (17.9) 
Disagree 49 (90.7) 27 (84.4) 23 (82.1) 
Cancer costs create a lot of stress 0.001 * 
Agree 13 (22.4) 4 (12.5) 16(51.6) 
Disagree 45 (77.6) 28 (87.5) 15(48.4) 
Cancer costs more stressful than other 
things 0.013* 
Agree 11 (19.0) 3 (9.1) 12 (38.7) 
Disagree 47 (81.0) 30 (90.9) 19(61.3) 
Trouble paying for my cancer costs 0.032* 
Agree 5 (8.8) 2 (6.2) 8 (25.8) 
Disagree 52 (91.2) 30 (93.8) 23 (74.2) 
Aware of assistance programs 0.567 
Agree 14 (23.7) 9 (27.3) 10 (34.5) 
Disagree 45 (76.3) 24 (72.7) 19 (65.5) 
Prescription drugs free to everyone 0.782 
Agree 40 (63.5) 18 (56.2) 20 (62.5) 
Disagree 23 (36.5) 14 (43.2) 12 (37.5) 
Prescription drugs free to low income people 0.752 
Agree 57 (86.4) 27 (81.8) 26 (81.2) 
Disagree 9 (13.6) 6 (18.2) 6 (18.8) 
Assistance programs well advertised 0.721 
Agree 9 (13.4) 3 (9.1) 5 (15.6) 
Disagree 58 (86.6) 30 (90.9) 27 (84.4) 
* Statistically significant; p<0.05 
M3. urban rural residents and one month OOP costs 
Table M11 presents the amount ofOOP costs incurred by urban and rural men. 
Compared to urban men, a larger proportion of rural had costs in excess of $500 in one 
month for travel related costs and all cancer related OOP costs. 
Table Mll. One month out-of-pocket costs, All Costs category, for urban and rural 
participants. 
Cost urban% rural 
n (%) n (%) p value 
Drugs and Supplies 1 Month(n = 170) 
$0 61 (78.2) 65 (70.7) 
$0.01 - $499.99 17 (21.8) 25 (27.2) 0.284 
>$500.00 0 (0.0) 2 (2.2) 
Travel 1 month (n = 170) 
$0 62 (79.5) 51 (55.4) 
$0.01 - $499.99 12 (15.4) 24 (26.1) 0.002* 
>$500.00 4 (5.1) 17 (18.5) 
All Costs 1 Month (n = 170) 
$0 51 (65.4) 44 (47.8) 
$0.01 - $499.99 23 (29.5) 28 (30.4) 0.005* 
>$500.00 4 (5.1) 20 (21.7) 
* Statistically significant; p<0.05 
Likewise, a larger proportion of rural men than urban men spent 7.5% of their 
income for travel related costs and all cancer related OOP costs (Tale M12). 
Table M12.Percent of income consumed (1 month) for urban rural participants. 
% of Income Consumed urban% rural 
n (%) n(%) pvalue 
Drugs and Supplies (n = 170) 
0% 61 (78.2) 65 (70.7) 
0.01 -7.49% 15 (19.2) 23 (25.0) 0.513 
7.50+% 2 (2.6) 4 (4.3) 
Travel (n = 169) 
0% 62 (79.5) 51 (55.4) 
0.01 -7.49% 9 (11.5) 16 (17.4) 0.002* 
7.50+% 7 (9.0) 25 (27.2) 
All costs (n = 170) 
0% 51 (65.4) 44 (47.8) 
0.01 -7.49% 20 (25.6) 19(20.7) 0.002* 
7.50+% 7 (9.0) 29 (31.5) 
* Statistically significant; p<0.05 




